Document:

EX-10.44

 Exhibit 10.44 
 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. 
 Confidential Treatment Requested Under 
 17 C.F.R. Sections
200.80(b)(4) and 240.24b-2 
 CONFIDENTIAL 

Execution Version 
 LICENSE AGREEMENT 
 By and between 

AstraZeneca AB 
 and 
 Horizon Pharma USA, Inc. 

Dated as of November 22, 2013 

							
		
	 ARTICLE 1 DEFINITIONS
	  	 	1	  
		
	 ARTICLE 2 GRANT OF RIGHTS; ALLIANCE MANAGEMENT
	  	 	5	  
			
	 2.1
	    	Grants to Horizon	  	 	5	  
			
	 2.2
	    	Sublicenses	  	 	6	  
			
	 2.3
	    	Grants to AstraZeneca	  	 	7	  
			
	 2.4
	    	Retention of Rights	  	 	8	  
			
	 2.5
	    	No Implied Rights	  	 	9	  
			
	 2.6
	    	Restrictions	  	 	9	  
			
	 2.7
	    	Horizon Control in Horizon Territory	  	 	10	  
			
	 2.8
	    	Alliance Management	  	 	10	  
		
	 ARTICLE 3 TERRITORIAL RESTRICTIONS; COMPLIANCE
	  	 	10	  
			
	 3.1
	    	Horizon Restrictions	  	 	10	  
			
	 3.2
	    	AstraZeneca Restrictions	  	 	11	  
			
	 3.3
	    	Compliance with Legal Requirements	  	 	11	  
			
	 3.4
	    	Compliance with Ethical Business Practices	  	 	11	  
		
	 ARTICLE 4 REGULATORY
	  	 	12	  
			
	 4.1
	    	Regulatory Responsibilities	  	 	12	  
			
	 4.2
	    	Access to Regulatory Approvals and Documentation	  	 	14	  
			
	 4.3
	    	Pharmacovigilance Obligations	  	 	15	  
			
	 4.4
	    	Post-Closing Responsibility for Product	  	 	15	  
		
	 ARTICLE 5 RECORDS
	  	 	16	  
			
	 5.1
	    	Records	  	 	16	  
			
	 5.2
	    	Review of Horizon Financial Records	  	 	16	  
		
	 ARTICLE 6 ASTRAZENECA PATENTS
	  	 	16	  
			
	 6.1
	    	Maintenance and Prosecution of AstraZeneca Patents	  	 	16	  

							
			
	 6.2
	    	Enforcement of AstraZeneca Patents	  	 	17	  
			
	 6.3
	    	Infringement Claims by Third Parties	  	 	18	  
			
	 6.4
	    	Invalidity or Unenforceability Defenses or Actions	  	 	19	  
			
	 6.5
	    	Statements or Actions Pertaining to Esomeprazole or Nexium	  	 	19	  
		
	ARTICLE 7 LICENSED TRADEMARKS	  	 	20	  
			
	 7.1
	    	Use of Licensed Trademarks	  	 	20	  
			
	 7.2
	    	Approval Procedures	  	 	21	  
			
	 7.3
	    	Clearance, Registration, Prosecution and Maintenance of Licensed Trademarks	  	 	21	  
			
	 7.4
	    	Enforcement and Defense of Licensed Trademarks	  	 	22	  
			
	 7.5
	    	No Implied Rights	  	 	23	  
			
	 7.6
	    	Other Trademarks	  	 	23	  
		
	ARTICLE 8 LICENSED DOMAIN NAMES	  	 	23	  
			
	 8.1
	    	Ownership and Goodwill	  	 	23	  
			
	 8.2
	    	Registration and Maintenance	  	 	23	  
			
	 8.3
	    	Control of Licensed Domain Name Websites	  	 	23	  
			
	 8.4
	    	Country-Specific Traffic	  	 	24	  
			
	 8.5
	    	Enforcement	  	 	24	  
		
	ARTICLE 9 CONFIDENTIALITY AND NON-DISCLOSURE	  	 	25	  
			
	 9.1
	    	General	  	 	25	  
			
	 9.2
	    	Other Nexium Communications	  	 	26	  
			
	 9.3
	    	Certain Permitted Esomeprazole and Nexium Disclosures	  	 	27	  
			
	 9.4
	    	Press Releases	  	 	27	  
		
	ARTICLE 10 DISCLAIMER OF WARRANTIES	  	 	27	  
		
	 ARTICLE 11 INDEMNITY
	  	 	27	  

  
 - ii -

							
			
	 11.1
	    	Indemnification of AstraZeneca	  	 	27	  
			
	 11.2
	    	Indemnification of Horizon	  	 	28	  
			
	 11.3
	    	Indemnification Procedures	  	 	28	  
			
	 11.4
	    	Limitation on Damages and Liability	  	 	28	  
			
	 11.5
	    	Insurance	  	 	28	  
		
	 ARTICLE 12 TERM AND TERMINATION
	  	 	29	  
			
	 12.1
	    	Term	  	 	29	  
			
	 12.2
	    	Termination for Material Breach	  	 	29	  
			
	 12.3
	    	Mutual Agreement	  	 	29	  
			
	 12.4
	    	Consequences of Termination	  	 	29	  
		
	 ARTICLE 13 MISCELLANEOUS
	  	 	30	  
			
	 13.1
	    	Governing Law, Jurisdiction, Venue and Service	  	 	30	  
			
	 13.2
	    	Dispute Resolution	  	 	31	  
			
	 13.3
	    	Notices	  	 	32	  
			
	 13.4
	    	No Benefit to Third Parties	  	 	33	  
			
	 13.5
	    	Waiver and Non-Exclusion of Remedies	  	 	33	  
			
	 13.6
	    	Expenses	  	 	33	  
			
	 13.7
	    	Assignment	  	 	34	  
			
	 13.8
	    	Use of Affiliates, Third Party Subcontractors	  	 	34	  
			
	 13.9
	    	Amendment	  	 	34	  
			
	 13.10
	    	Independent Contractors	  	 	34	  
			
	 13.11
	    	Severability	  	 	34	  
			
	 13.12
	    	Equitable Relief	  	 	35	  
			
	 13.13
	    	English Language	  	 	35	  
			
	 13.14
	    	Counterparts	  	 	35	  

  
 - iii -

							
	 13.15
	    	Entire Agreement	  	 	35	  
			
	 13.16
	    	Construction	  	 	35	  

  

			
	SCHEDULES	  	
		
	 Schedule 1.29
	  	Licensed Trademarks

  
 - iv -

 LICENSE AGREEMENT 

This License Agreement (this “Agreement”) is made and entered into effective as of November 22, 2013 (the
“Effective Date”) by and between AstraZeneca AB, a Swedish corporation (“AstraZeneca”), and Horizon Pharma USA, Inc., a corporation organized and existing under the Laws of the State of Delaware
(“Horizon”). AstraZeneca and Horizon are sometimes referred herein individually as a “Party” and collectively as the “Parties.” 

RECITALS 

WHEREAS, AstraZeneca and Horizon are parties to that certain Asset Purchase Agreement, dated as of November 18, 2013 (the
“Asset Purchase Agreement”), pursuant to which, effective as of the Closing, Horizon is purchasing from AstraZeneca certain assets related to the Product (as defined in the Asset Purchase Agreement) in the Horizon Territory (as
defined in the Asset Purchase Agreement) and AstraZeneca is required to grant a license or right of reference and use to Horizon, and Horizon is required to take a license or right of reference and use, under certain intellectual property,
regulatory data and approvals, to Exploit the Product and Other Products in the Horizon Territory; and 
 WHEREAS,
following the Closing, Horizon will Control certain regulatory data and approvals with respect to the Product and is required to grant a right of reference and use to AstraZeneca, and AstraZeneca is required to take a right of reference, under such
regulatory data and approvals with respect to the Product, to Exploit the Product and Other Products in the AstraZeneca Territory. 
 NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions hereinafter set forth and set forth in the Asset Purchase Agreement, the other Ancillary Agreements, and
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows: 
 ARTICLE 1 
 DEFINITIONS 

Unless otherwise specifically provided herein, the following terms shall have the meanings set forth in this Article 1 and capitalized terms used but not
otherwise defined herein shall have the respective meanings ascribed thereto in the Asset Purchase Agreement. 
 1.1
“AAA” has the meaning set forth in Section 13.2.2. 
 1.2 “Agreement” has the meaning set
forth in the preamble hereto. 
 1.3 “Alliance Manager” has the meaning set forth in Section 2.8. 

1.4 “Ancillary AstraZeneca Confidential Information” has the meaning set forth in Section 9.1.3. 

1.5 “Ancillary Confidential Information” has the meaning set forth in Section 9.1.1. 

 1.6 “Ancillary Disclosing Party” has the meaning set forth in Section
9.1.1. 
 1.7 “Ancillary Horizon Confidential Information” has the meaning set forth in Section 9.1.2.

 1.8 “Ancillary Receiving Party” has the meaning set forth in Section 9.1.1. 

1.9 “Anti-Corruption Laws” means the Foreign Corrupt Practices Act of 1977, as amended, the Anti-Kickback Act of 1986, as
amended, the UK Bribery Act of 2012, and the Anti-Bribery Laws of the People’s Republic of China or any applicable Laws of similar effect, and the related regulations and published interpretations thereunder. 

1.10 “Arbitration Notice” has the meaning set forth in Section 13.2.2. 

1.11 “Arbitrators” has the meaning set forth in Section 13.2.2. 

1.12 “Asset Purchase Agreement” has the meaning set forth in the recitals hereto. 

1.13 “AstraZeneca” has the meaning set forth in the preamble hereto. 

1.14 “AstraZeneca Indemnitees” has the meaning set forth in Section 11.1. 

1.15 “AstraZeneca Patents” has the meaning set forth in Section 6.1. 

1.16 “Breaching Party” has the meaning set forth in Section 12.2. 

1.17 “CCP” has the meaning set forth in Section 4.1.2. 

1.18 “Dispute” has the meaning set forth in Section 13.2.1. 

1.19 “Effective Date” has the meaning set forth in the preamble hereto. 

1.20 “Ex-US Licensed Patents” means the Patent Rights that are the foreign equivalents of the Merck Patents, excluding
any such Patent Rights included in the Manufacturing Technology. 
 1.21 “Existing Pediatric
Study” means that certain study entitled [...***...]. 

1.22 “Government Official” means (a) any Person employed by or acting on behalf of a government,
government-controlled agency or entity or public international organization, (b) any political party, party official or candidate, (c) any Person who holds or performs the duties of a public-sector appointment, office or position created
by custom or convention or (d) any Person who holds himself out to be the authorized intermediary of any of the foregoing. 

  
  

	***	Confidential Treatment Requested 

 - 2 - 

 1.23 “Horizon” has the meaning set forth in the preamble hereto.

 1.24 “Horizon Indemnitees” has the meaning set forth in Section 11.2. 

1.25 “Horizon Regulatory Documentation” means any and all Regulatory Documentation related to the Product or any Other
Product, in each case, Controlled by Horizon or any of its Affiliates effective at any time as of or following the Closing, including the Purchased Regulatory Approvals and any other Regulatory Documentation included in the Purchased Assets.

 1.26 “Licensed Intellectual Property” means the US Licensed Patents, the Ex-US Licensed Patents, the Licensed
Know-How, the Licensed Copyrights, the Licensed Trademarks, the Licensed Domain Names and the Manufacturing Technology. 
 1.27
“Licensed Know-How” means (a) as of the Effective Date, any data, information and know-how that (i) is not generally known, (ii) is Controlled by AstraZeneca or its Affiliates and (iii) is used by or on behalf of
AstraZeneca or its Affiliates as of the Effective Date for the Exploitation of the Product in the Horizon Territory or the research or development of the Product in the AstraZeneca Territory, excluding the Merck Know-How and (b) as of the date,
if any, that AstraZeneca or any of its Affiliates may grant a license to Horizon under the Merck Know-How without violating the terms of any Merck Agreement, (i) the data, information and know-how described in clause (a) and (ii) the
Merck Know-How used by or on behalf of AstraZeneca or its Affiliates as of the Effective Date for the Exploitation of the Product in the Horizon Territory; provided, that in either case ((a) or (b)), if such data, information or know-how
becomes publicly disclosed (other than as a result of any disclosure by Horizon in breach of its obligations under Section 9.1), such data, information or know-how shall no longer be deemed Licensed Know-How, but excluding in either case ((a)
or (b)) any data, information and know-how included in the Manufacturing Technology. 
 1.28 “Licensed Regulatory
Documentation” means any and all Regulatory Documentation related to the Product or any Other Product, in each case, Controlled by AstraZeneca or any of its Affiliates as of and following the Closing, excluding the Regulatory Documentation
included in the Purchased Assets. 
 1.29 “Licensed Trademarks” means (a) the Trademark VIMOVO and the
other Trademarks and logos listed on Schedule 1.29 and (b) any variation or derivation of any of the Trademarks set forth in the foregoing clause (a) that are approved by AstraZeneca in accordance with the procedures set forth in
Section 7.2.1 for use on or in connection with the Exploitation of the Product or any Other Product in the Horizon Territory. 
 1.30 “Manufacturing Technology” means (a) as of the Effective Date, all Patent Rights (including foreign equivalents of the Merck Patents) and all data, information and know-how that
(i) with respect to data, information and know-how, is not generally known, (ii) are Controlled by AstraZeneca or any of its Affiliates as of the Effective Date and (iii) are used

  
 - 3 -

 
by or on behalf of AstraZeneca or its Affiliates for the Manufacture of Products or Other Products as of the Effective Date, excluding the Merck Patents and Merck Know-How and (b) as of the
date, if any, that AstraZeneca or any of its Affiliates may grant a license to Horizon under the Merck Patents and Merck Know-How without violating the terms of any Merck Agreement, the Patent Rights, data, information and know-how described in
clause (a) and any Merck Patents and Merck Know-How that are used by or on behalf of AstraZeneca or its Affiliates for the Manufacture of Products or Other Products as of the Effective Date; provided, that in either case ((a) or (b)), if
any data, information or know-how (but not, for clarity, Patent Rights) included in Manufacturing Technology becomes publicly disclosed (other than as a result of any disclosure by Horizon in breach of its obligations under Section 9.1), such
data, information or know-how shall no longer be deemed Manufacturing Technology. 
 1.31 “Merck Net
Sales” means, for any period of time, the total amount required to be recorded for such period by Horizon or any of its Affiliates or Sublicensees on its or their respective books and records in accordance with GAAP with respect to sales of
Merck Product in the Horizon Territory for any use (whether in human medicine or otherwise) to its non-Affiliates after deducting (if not already deducted in the amount recorded) trade discounts, rebates, returns and allowances, retroactive price
reductions or adjustments, and [...***...] of the amount recorded to cover cash discounts (“fast
pay”), sales or excise taxes, transportation, and insurance charges. 
 1.32 “Notice” has the meaning set
forth in Section 13.3.1. 
 1.33 “Notice Period” has the meaning set forth in Section 12.2.

 1.34 “Other Esomeprazole Product” means any Other Product that contains Esomeprazole as an active ingredient.

 1.35 “Party” and “Parties” each has the meaning set forth in the preamble hereto.

 1.36 “Payment” has the meaning set forth in Section 3.4.1(b). 

1.37 “Primary Licensed Domain Name” means vimovo.com. 

1.38 “Product Label” means, with respect to the Product or any Other Product in the Horizon Territory, (a) the
Regulatory Authority-approved full prescribing information for the Product or any Other Product, as applicable, including any required patient information and (b) all labels and other written, printed or
graphic matter upon a container, wrapper or any package insert utilized with or for the Product or any Other Product, as applicable. 
 1.39 “Product Websites” has the meaning set forth in Section 8.3. 
 1.40 “Recipients” means, with respect to a Party, such Party’s and its Affiliates’ respective officers, employees, agents, attorneys, consultants, contractors, advisors and
other representatives. 
  

  
  

	***	Confidential Treatment Requested 

 - 4 - 

 1.41 “Representatives” has the meaning set forth in Section 3.4.1(b).

 1.42 “Secondary Licensed Domain Names” means any Licensed Domain Name other than the Primary Domain Name.

 1.43 “Senior Officer” means, with respect to AstraZeneca, its Vice President, Cornerstone and Commercial
Excellence and with respect to Horizon, its Chief Executive Officer. 
 1.44 “Sublicensee” means a Third Party
that is granted a sublicense (or further rights of reference and use) by Horizon under the grant in Section 2.1 or by AstraZeneca under the grant in Section 2.3, in either case, in accordance with Section 2.2. 

1.45 “Term” has the meaning set forth in Section 12.1. 

1.46 “Terminable Rights and Provisions” means (a) the licenses granted by AstraZeneca to Horizon under
Section 2.1 with respect to the Licensed Trademarks and Licensed Domain Names only (but not, for clarity, with respect to any other Licensed Intellectual Property or Licensed Regulatory Documentation), (b) Article 7 and (c) Article 8.

 1.47 “Third Party Claims” has the meaning set forth in Section 11.1. 

1.48 “US Licensed Patents” means as of the date, if any, that AstraZeneca or any of its Affiliates may grant a license to
Horizon under the Merck Patents without violating the terms of any Merck Agreement, the Merck Patents, excluding any Merck Patents included in the Manufacturing Technology. 
 ARTICLE 2 
 GRANT OF RIGHTS; ALLIANCE MANAGEMENT 

2.1 Grants to Horizon. Subject to Section 2.4 and the other terms and conditions of the Asset Purchase Agreement and
this Agreement, AstraZeneca (on behalf of itself and its Affiliates), in consideration of the amounts due under the Asset Purchase Agreement, hereby grants to Horizon and its Affiliates: 

2.1.1 an exclusive (even as to AstraZeneca and its Affiliates), royalty-free, non-transferable (except as provided in Section 13.7)
license, with the right to grant sublicenses in accordance with Section 2.2, under the Licensed Copyrights, Licensed Trademarks, Licensed Domain Names, US Licensed Patents, and Licensed Know-How to Exploit the Product or any Other Product in
the Field in the Horizon Territory; 
 2.1.2 an exclusive (even as to AstraZeneca and its Affiliates), royalty-free,
non-transferable (except as provided in Section 13.7) license, with the right to grant sublicenses in accordance with Section 2.2, under the Manufacturing Technology, the Licensed Trademarks and the Licensed Copyrights to Manufacture or
have Manufactured the Product or any Other Product in the Field in the Horizon Territory; 
 2.1.3 a non-exclusive,
royalty-free, non-transferable (except as provided 

  
 - 5 -

 
in Section 13.7) license, with the right to grant sublicenses in accordance with Section 2.2, under the Manufacturing Technology, the Licensed Trademarks and the Licensed Copyrights to
Manufacture and have Manufactured the Product or any Other Product in the AstraZeneca Territory but solely for the exportation and use of such Product or Other Product in connection with the Exploitation of the Product or any Other Product in the
Field in the Horizon Territory; 
 2.1.4 a non-exclusive, royalty-free, non-transferable (except as provided in
Section 13.7) license, with the right to grant sublicenses in accordance with Section 2.2, under the Licensed Copyrights, Ex-US Licensed Patents, and Licensed Know-How to (a) perform research and development activities with respect to
the Product or any Other Product in the AstraZeneca Territory solely in connection with the Manufacture and Exploitation of the Product or any Other Product in the Horizon Territory, and (b) to export or import the Product or any Other Product
in the AstraZeneca Territory solely in connection with the Manufacture and Exploitation of the Product or any Other Product in the Horizon Territory; and 
 2.1.5 a non-exclusive, royalty-free, non-transferable (except as provided in Section 13.7) right of reference and use, with the right to grant further rights of reference and use in accordance with
Section 2.2, under the Licensed Regulatory Documentation to (a) Manufacture, have Manufactured or Exploit the Product or any Other Product in the Field in the Horizon Territory, (b) Manufacture and have Manufactured the Product or any
Other Product in the AstraZeneca Territory but solely for the exportation and use of such Product or Other Product in connection with the Manufacture and Exploitation of the Product or any Other Product in the Field in the Horizon Territory, and
(c) perform research and development activities with respect to, and export and import, the Product or any Other Product in the AstraZeneca Territory solely in connection with the Manufacture and Exploitation of the Product or any Other Product
in the Horizon Territory. 
 All licenses granted under this Section 2.1 shall be perpetual and irrevocable except as
otherwise provided in Article 12 with respect to the termination of the Terminable Rights and Provisions. 

2.2 Sublicenses. Horizon shall have the right to grant sublicenses (or further rights of reference and
use) under the licenses and rights of reference and use granted in Section 2.1, through multiple tiers of Sublicensees, and AstraZeneca shall have the right to grant sublicenses (or further rights of reference and use) under the licenses and
rights of reference and use granted in Section 2.3, through multiple tiers of Sublicensees; provided, however, that any such sublicense granted by Horizon with respect to any Manufacturing Technology related to Esomeprazole under
Section 2.1.2 or Section 2.1.3 shall be subject to AstraZeneca’s prior written consent, which consent may be granted or withheld in its sole discretion; provided, further, that AstraZeneca shall not condition, withhold or delay
its consent to any such sublicense to be granted by Horizon or any of its Affiliates to any Third Party if, at the time of such proposed sublicense, such Third Party is supplying Esomeprazole to AstraZeneca or any of its Affiliates or any of its or
their respective licensees or sublicensees. Notwithstanding the foregoing, AstraZeneca acknowledges and agrees that Horizon intends to grant [...***...] a non-exclusive, sublicense (or further rights of reference and use) under the licenses and rights of reference and use granted in Section 2.1.2 or
2.1.3 solely for the purposes of [...***...] supplying Esomeprazole to Horizon for use in the Manufacture of the Product for Exploitation in 

  
  

	***	Confidential Treatment Requested 

 - 6 - 

 
the Horizon Territory, and AstraZeneca hereby consents to such sublicense. AstraZeneca agrees that neither AstraZeneca nor any of its Affiliates shall claim (or assist a Third Party in claiming)
that the further formulation or other processing of Esomeprazole by or on behalf of Horizon or its Affiliates or any Sublicensee in connection with the Manufacture of the Product or any Other Product in the Horizon Territory or in the AstraZeneca
Territory but solely for the exportation and use of such Product or Other Product in accordance with this Agreement, infringes or misappropriates any Patent Rights, information, data or know-how that are part of the Manufacturing Technology and that
Horizon or its Affiliates or any Sublicensee shall have the right to formulate or otherwise process, or have a Third Party formulate or otherwise process on their behalf, any Esomeprazole from [...***...] or any other Third Party to whom Horizon or any of its Affiliates grants a sublicense to any Manufacturing Technology related to Esomeprazole with
AstraZeneca’s consent in connection with the Manufacture of the Product or any Other Product in the Horizon Territory or in the AstraZeneca Territory but solely for the exportation and use of such Product or Other Product in accordance with
this Agreement. Further, if AstraZeneca or any of its Affiliates assigns or transfers any Patent Rights that are part of the Manufacturing Technology, AstraZeneca or such Affiliate shall cause such assignee or transferee to be bound by the covenant
set forth in the immediately foregoing sentence. Each Party granting a sublicense pursuant to this Section 2.2 shall (a) remain jointly and severally liable for the performance or non-performance of any such Sublicensee, and
(b) provide to the other Party within 14 days after execution by the parties thereto a written notice setting forth in reasonable detail the nature of such sublicense and the identity of the Sublicensee, which written notice shall include a
copy of such executed sublicense agreement; provided that the financial terms and any other commercially sensitive terms of any such sublicense agreement may be redacted to the extent not pertinent to an understanding of either Party’s
obligations or benefits under this Agreement. The grant of any such sublicense shall not relieve the sublicensing Party of its obligations under this Agreement, except to the extent such obligations are performed by any such Affiliate or
Sublicensee. Notwithstanding anything to the contrary herein, neither Party shall be responsible or liable for the other Party’s or its Affiliates’ (or their respective sub-sublicensees’) performance or exercise of any sublicense
granted by the first Party to such other Party or its Affiliates under Section 2.1 or Section 2.3, as applicable. 

2.3 Grants to AstraZeneca. Subject to the terms and conditions of this Agreement, Horizon (on behalf of itself and its
Affiliates and sublicensees) hereby grants to AstraZeneca and its Affiliates: 
 2.3.1 a non-exclusive, royalty-free,
non-transferable (except as provided in Section 13.7) license, with the right to grant sublicenses in accordance with Section 2.2, under the Manufacturing Technology, the Licensed Trademarks and the Licensed Copyrights to Manufacture or
have Manufactured the Product or any Other Product in the Horizon Territory but solely for the exportation and use of such Product or Other Product in connection with the Exploitation of the Product or any Other Product in the AstraZeneca Territory;

 2.3.2 a non-exclusive, royalty-free, non-transferable (except as provided in Section 13.7) license, with the right to
grant sublicenses in accordance with Section 2.2, under the Licensed Copyrights, US Licensed Patents, and Licensed Know-How to (a) perform research and development activities with respect to the Product or any Other Product in the Horizon

  
  

	***	Confidential Treatment Requested 

 - 7 - 

 
Territory solely in connection with the Exploitation of the Product or any Other Product in the AstraZeneca Territory, and (b) to export or import the Product or any Other Product in the
Horizon Territory solely in connection with the Exploitation of the Product or any Other Product in the AstraZeneca Territory; and 
 2.3.3 a non-exclusive, royalty-free, non-transferable (except as provided in Section 13.7) right of reference and use, with the right to grant further rights of reference and use in accordance with
Section 2.2, under the Horizon Regulatory Documentation to (a) Manufacture, have Manufactured or Exploit the Product or any Other Product in the Field in the AstraZeneca Territory, (b) Manufacture and have Manufactured the Product or
any Other Product in the Horizon Territory but solely for the exportation and use of such Product or Other Product in connection with the Manufacture and Exploitation of the Product or any Other Product in the Field in the AstraZeneca Territory, and
(c) perform research and development activities with respect to, and export and import, the Product or any Other Product in the Horizon Territory solely in connection with the Manufacture and Exploitation of the Product or any Other Product in
the AstraZeneca Territory. 
 2.4 Retention of Rights. 

2.4.1 Except for the rights and licenses expressly granted to Horizon and Affiliates in this Agreement or in any other Ancillary
Agreement, AstraZeneca, on behalf of itself and its Affiliates, retains all rights under the Licensed Intellectual Property and the Licensed Regulatory Documentation. 
 2.4.2 Except for the rights and licenses expressly granted to AstraZeneca and Affiliates in this Agreement or in any other Ancillary Agreement,(a) Horizon, on behalf of itself and its Affiliates, retains
all rights under Horizon Regulatory Documentation and (b) Horizon, on behalf of its and its Affiliates, retains the exclusive right under (i) the Licensed Copyrights, Licensed Trademarks, Licensed Domain Names, US Licensed Patents, and
Licensed Know-How to Exploit the Product or any Other Product in the Field in the Horizon Territory and (ii) the Manufacturing Technology, the Licensed Trademarks and the Licensed Copyrights to Manufacture or have Manufactured the Product or
any Other Product in the Field in the Horizon Territory. 
 2.4.3 No rights shall be deemed granted by either Party to the other
Party by implication, estoppel or otherwise with respect thereto. 
 2.4.4 In addition, AstraZeneca, on behalf of itself and its
Affiliates, retains the non-exclusive right in the Horizon Territory under the Licensed Intellectual Property and Licensed Regulatory Documentation to perform its obligations under this Agreement, the Supply Agreement or Section 5.3 of the
Asset Purchase Agreement. 
 2.4.5 Except as expressly granted herein, in the Asset Purchase Agreement or
in any other Ancillary Agreement, (a) neither Party grants any right or license to any assets or rights, including intellectual property rights, of such Party and its Affiliates and
(b) [...***...] or [...***...]. 

  
  

	***	Confidential Treatment Requested 

 - 8 - 

 2.5 No Implied Rights. For the avoidance of doubt,
(a) Horizon and its Affiliates shall have no right, express or implied, except as expressly provided in Section 2.1 and elsewhere in this Agreement, the Asset Purchase Agreement, and the Ancillary Agreements with respect to (i) the
Licensed Intellectual Property or the Licensed Regulatory Documentation, and (ii) [...***...] and
(b) AstraZeneca and its Affiliates shall have no right, express or implied, with respect to the Horizon Regulatory Documentation, except as expressly provided in Section 2.3 and elsewhere in this Agreement and in Section 2.3.3 of the
Supply Agreement. For clarity, except for the licenses granted to Horizon and its Affiliates under the Licensed Trademarks and Licensed Domain Names, nothing herein grants either Party or any of its Affiliates the right to use or to register any
Domain Name (including both gTLDs and ccTLDs) or any social media name, tag or handle or similar identifier that incorporates in whole or in part any of the trade names, corporate names and corporate logos of the other Party or the other
Party’s Affiliates that are used by the other Party or any of the other Party’s Affiliates. 
 2.6
Restrictions. 
 2.6.1 Horizon shall not, and shall cause its Affiliates and Sublicensees not to, Exploit the
Product or any Other Product for any indication other than (a) one or more indications for which NSAIDs alone are indicated, together with (b) the prevention, treatment or amelioration of, or decrease in the risk of, gastrointestinal side
effectives of NSAIDs in patients at risk of developing side effects associated with NSAID use, so long as such prevention, treatment or amelioration of, or decrease in the risk of, gastrointestinal side effects is described or referenced in the
product prescribing information. 
 2.6.2 Without limiting the generality of Section 2.6.1, without the prior written
consent of AstraZeneca (which consent may be granted or withheld in its sole discretion), Horizon shall not, and shall cause its Affiliates and Sublicensees not to: 
 (a) conduct any pre-clinical or clinical studies or any epidemiological, health economic or other similar studies with respect to any Other Esomeprazole Product; 

(b) develop or seek Regulatory Approval for any Other Esomeprazole Product; 

(c) develop or seek Regulatory Approval for the Product outside of the Field; 

(d) refer to, or make any comparisons to, Nexium, any Nexium Trademark or the Nexium Business in advertising or promotional materials or
otherwise (including any internet or social media campaigns); 
 (e) use any advertising or promotional campaign elements or
phrases, logos, slogans or branding that are the same as or confusingly similar to those used with respect to Nexium anywhere in the world; 

  
  

	***	Confidential Treatment Requested 

 - 9 - 

 (f) use the color purple or any phrase that includes the term “purple” to
identify the Product or any Other Product; 
 (g) use any Trademark that is confusingly similar to any Nexium Trademark; or

 (h) use any purple packaging or other trade dress with a purple color scheme with respect to the Product or any Other
Product, including the physical appearance of the Product or any Other Product. 
 2.6.3 In the event that a Party intends to
conduct any pre-clinical or clinical studies or any epidemiological, health economic or other similar studies with respect to the Product, other than the Existing Pediatric Study, such Party shall notify the other Party in writing of its intent to
carry out such study and shall consider in good faith the other Party’s comments with respect to such proposed study. 
 2.7
Horizon Control in Horizon Territory. Subject to the terms of this Agreement, the Asset Purchase Agreement and the Supply Agreement, from and after the Effective Date, Horizon shall have the sole right and responsibility with respect to the
Manufacture and Exploitation of Products and Other Products in the Horizon Territory. 
 2.8 Alliance Management.
The Parties each acknowledge and agree that it would be beneficial to each to have a representative to act as an alliance manager (“Alliance Manager”) and shall appoint such a person promptly after the Effective Date. The Alliance
Managers shall serve as a single point of contact within each Party and shall coordinate as necessary with respect to the Products and the Other Products from time to time. If a Party needs to access any information or documentation of the other
Party or any of its Affiliates that is related to any Product or Other Product in order to comply with applicable Law or any Regulatory Authority requirement, to the extent such access is not otherwise provided under this Agreement or the Asset
Purchase Agreement, the Alliance Managers shall coordinate to provide such first Party appropriate access to such information or documents to the extent necessary for such first Party or its Affiliate to comply with applicable Law or any Regulatory
Authority requirement. 
 ARTICLE 3 
 TERRITORIAL RESTRICTIONS; COMPLIANCE 
 3.1 Horizon Restrictions.
Horizon (a) shall, and shall cause its Affiliates and its and their respective Sublicensees and distributors to, distribute, market, promote, offer for sale and sell the Product and the Other Products only in the Horizon Territory, and
(b) shall not, and shall not permit its Affiliates and its and their respective Sublicensees or distributors to, distribute, market, promote, offer for sale or sell the Product or any Other Product directly or indirectly to any Person for use
in the AstraZeneca Territory. If Horizon or any of its Affiliates receives or becomes aware of the receipt by a Sublicensee or distributor of any orders for the Product or any Other Product in the AstraZeneca Territory, such Person shall refer such
orders to AstraZeneca. Horizon shall cause its Affiliates and its and their respective Sublicensees and distributors to notify Horizon of any receipt of any orders for the Product or any Other Product in

  
 - 10 -

 
the AstraZeneca Territory. 
 3.2 AstraZeneca Restrictions.
AstraZeneca (a) shall, and shall cause its Affiliates and its and their respective licensees, sublicensees and distributors to, distribute, market, promote, offer for sale and sell the Product and the Other Products only in the AstraZeneca
Territory, and (b) shall not, and shall not permit its Affiliates and its and their respective licensees, sublicensees or distributors to, distribute, market, promote, offer for sale or sell the Product or any Other Product directly or
indirectly to any Person for use in the Horizon Territory. If AstraZeneca or any of its Affiliates receives or becomes aware of the receipt by a licensee, sublicensee or distributor of any orders for the Product or any Other Product in the Horizon
Territory, such Person shall refer such orders to Horizon. AstraZeneca shall cause its Affiliates and its and their respective licensees, sublicensees and distributors to notify AstraZeneca of any receipt of any orders for the Product or any Other
Product in the Horizon Territory. 
 3.3 Compliance with Legal Requirements. Horizon shall conduct, and shall cause its
Affiliates, Sublicensees, and Third Party subcontractors and distributors to conduct, all activities concerning the Product, any Other Product, the Licensed Intellectual Property and the Licensed Regulatory Documentation in compliance with all
applicable Laws. AstraZeneca shall conduct, and shall cause its Affiliates, licensees, sublicensees, and Third Party subcontractors and distributors to conduct, all activities concerning the Product and any Other Product in compliance with all
applicable Laws. In addition, each Party hereby certifies that it has not employed or otherwise used in any capacity, and will not employ or otherwise use in any capacity, the services of any Person debarred under United States Law, including 21
U.S.C. Section 335a (or any foreign equivalent thereof) or who is the subject of a conviction described in such section (or any foreign equivalent thereof), in connection with the Manufacture or Exploitation of the Product or any Other Product
or the performance of any portion of its activities hereunder or pursuant hereto. Each Party shall notify the other Party in writing immediately if any such debarment or conviction occurs or comes to its attention or if any Litigation is pending or,
to such Party’s knowledge, is threatened, relating to the debarment or conviction of such Party or any such Person, and shall, with respect to any Person so debarred or convicted promptly remove such Person from performing any activities in
connection with the Exploitation of the Product or any Other Product or the performance of any portion of such Party’s activities hereunder or pursuant hereto. 
 3.4 Compliance with Ethical Business Practices. 
 3.4.1
Anti-Bribery and Anti-Corruption Compliance. 
 (a) Each Party acknowledges that the other Party’s corporate policy
requires that such other Party’s business must be conducted within the letter and the spirit of the Law and consistent with good business ethics. By signing this Agreement, each Party agrees to conduct its activities under this Agreement
(including, in the case of AstraZeneca, Manufacture, research, development, import and export of Products and Other Products in the Horizon Territory, and the Manufacture and Exploitation of Products and Other Products in the AstraZeneca Territory)
in a manner that is consistent with Law, including Anti-Corruption Law, and good business ethics. 

  
 - 11 -

 (b) Neither Party shall, or permit its Affiliates to, and each Party shall use its
commercially reasonable efforts to not permit its Sublicensees, agents, contractors and other representatives to, pay, offer or promise to pay, or authorize the payment of any money, or give, offer or promise to give, or authorize the giving of
anything of value (collectively, a “Payment”) to any Government Official in connection with the Manufacture or Exploitation of Products or Other Products where such Payment would constitute a violation of any Anti-Corruption Law. In
addition, regardless of legality, neither Party shall make any Payment, directly or indirectly, to any Government Official in connection with the Manufacture or Exploitation of Products or Other Products if such Payment is for the purpose of
influencing decisions or actions in connection with the Manufacture or Exploitation of Products or Other Products. Each Party acknowledges and agrees that none of the other Party, or any of its Affiliates or its or their respective officers,
directors, employees, agents and representatives (collectively, “Representatives”) is authorized to waive compliance with the provisions of this Section 3.4.1(b) and that it shall be solely responsible for its compliance with
the provisions of this Section 3.4.1(b) and the Anti-Corruption Laws irrespective of any act or omission of the other Party or any of its Affiliates or its or their respective Representatives. 

3.4.2 Exclusions List. Horizon shall not use (and shall cause its Affiliates not to use) any Person (including any employee,
officer, director, Sublicensee or Third Party contractor or distributor) who is (or has been) on the Exclusions List of the Office of Inspector General, U.S. Department of Health & Human Services, or who is (or has been) in violation of the
terms hereof in connection with the Manufacture or Exploitation of Products or Other Products. Horizon certifies to AstraZeneca that, as of the Effective Date, Horizon has screened itself, and its officers and directors (and its Affiliates,
Sublicensees and Third Party contractors and distributors and their respective officers and directors) against the Exclusions List of the Office of Inspector General, U.S. Department of Health & Human Services and that it has informed
AstraZeneca whether Horizon, or any of its officers or directors (or any of its Affiliates, Sublicensees or Third Party contractors or distributors or any of their respective officers and directors) has been in violation of the terms hereof in
connection with the performance of any activities hereunder. After the execution of this Agreement, Horizon shall promptly notify AstraZeneca in writing if any such violation comes to its attention. 

ARTICLE 4 

REGULATORY 

4.1 Regulatory Responsibilities. 
 4.1.1 Notification of Label Changes. 
 (a) Horizon shall notify AstraZeneca
in writing of any revisions to the Product Label for the Product or any Other Product in the Horizon Territory whether initiated by Horizon or requested by FDA within 10 days after such revision is initiated by Horizon or requested by FDA, as
applicable. Horizon shall also notify AstraZeneca in writing of any revision to the Product Label for the Product or any Other Product in the Horizon Territory within 10 days after such revision is approved by FDA, and such notice shall include the
exact revised language for the applicable Product Label. 

  
 - 12 -

 (b) AstraZeneca shall notify Horizon in writing of any revisions whether initiated by
AstraZeneca or requested by any Regulatory Authority to (i) the Regulatory Authority approved full prescribing information for the Product or any Other Product in the AstraZeneca Territory, including any required patient information and all
labels and other written, printed or graphic matter upon a container, wrapper or any package insert utilized with or for the Product or any Other Product in the AstraZeneca Territory or (ii) the Regulatory Authority approved full prescribing
information for Nexium anywhere in the world, including any required patient information and all labels and other written, printed or graphic matter upon a container, wrapper or any package insert utilized with or for Nexium anywhere in the world,
in either case ((i) or (ii)) that would reasonably be expected to impact the Product Label for the Product or any Other Product in the Horizon Territory within 10 days after such revision is initiated by AstraZeneca or requested by the applicable
Regulatory Authority, as applicable. AstraZeneca shall also notify Horizon in writing of any such revisions within 10 days after such revision is approved by the applicable Regulatory Authority, and such notice shall include the exact revised
language for the application revision. 
 (c) The Party notifying the other Party of any revisions to any Regulatory Authority-approved full prescribing information, including any required patient information or any labels and other written, printed or graphic matter upon a container, wrapper or any package insert pursuant to this
Section 4.1.1, shall use commercially reasonable efforts to answer the other Party’s questions with respect to any such revision. 
 (d) For clarity, the Parties obligations under this Section 4.1.1 are in addition to any other notification obligations either Party has under the Transition Safety Data Exchange Agreement or the
Post-Transition Safety Data Exchange Agreement. 
 4.1.2 If a legalized Certificate of Pharmaceutical Product (“CPP”)
is required to renew any Regulatory Approval for a Product or Other Product in any country in the AstraZeneca Territory, upon AstraZeneca’s reasonable request with respect to timing, Horizon shall use commercially reasonable efforts to assist
AstraZeneca in obtaining such CPP. AstraZeneca shall provide Horizon with reasonable advance notice of the need for any such CPP and such notice shall contain sufficient information and instructions as to minimize impact into Horizon’s normal
business activities. The Alliance Managers shall coordinate with respect to any request for a CPP by AstraZeneca to ensure that such request is handled promptly and with reasonable care. Upon AstraZeneca’s request for any CPP, the Parties shall
agree upon the process cost and timelines with respect thereto. AstraZeneca shall reimburse Horizon for all reasonable and documented or otherwise verifiable external and internal costs incurred in connection with processing or otherwise assisting
AstraZeneca in obtaining any requested CPP, including the full time equivalent costs of the employees of Horizon involved in processing any requested CPP or otherwise assisting AstraZeneca in obtaining any requested CPP (which shall be calculated at
a rate to be agreed to by the Parties), to the extent such costs do not exceed the costs agreed to by the Parties pursuant to the immediately preceding sentence. AstraZeneca shall reimburse Horizon for such costs within 45 days after receipt of an
invoice and reasonable supporting documentation with respect to such costs. 
 4.1.3 Notwithstanding anything to the contrary in
this Agreement, if Horizon is required by applicable Law to provide a Regulatory Authority any communication 

  
 - 13 -

 
that relates to [...***...] and [...***...] as it
[...***...] that [...***...] to [...***...]. 
 4.2 Access to Regulatory Approvals and Documentation. 

4.2.1 Upon Horizon’s reasonable request with respect to timing of delivery, AstraZeneca promptly shall (a) provide to
Horizon, at Horizon’s cost and expense, copies of the Licensed Regulatory Documentation solely for purposes of exercising Horizon’s and its Affiliates’ rights under the grants in Section 2.1 and (b) provide to Horizon and to
any specified Governmental Authority in the Horizon Territory a letter, in the form reasonably requested by Horizon, acknowledging that Horizon has the right of reference and use to any Licensed Regulatory Documentation as described under
Section 2.1.5. Notwithstanding anything to the contrary contained in this Agreement, AstraZeneca shall not be required to disclose any information contained in the Licensed Regulatory Documentation or provide any such access to such information
if such disclosure or access would, in AstraZeneca’s reasonable discretion, (x) violate (i) applicable Law or (ii) any binding agreement entered into by AstraZeneca prior to the Effective Date, including any confidentiality
agreement to which AstraZeneca is a party (provided, that AstraZeneca shall use commercially reasonable efforts to obtain consent from any Third Party to any such binding agreement to enable AstraZeneca to disclose such information),
(y) jeopardize any attorney/client privilege or other established legal privilege or (z) disclose any trade secrets; provided, that AstraZeneca shall provide Horizon with a general description of the type of any such information
redacted or withheld by AstraZeneca to the extent that AstraZeneca is permitted to do so and keep Horizon informed of all efforts undertaken by AstraZeneca to enable AstraZeneca to disclose such redacted or withheld information to Horizon.

 4.2.2 Upon AstraZeneca’s reasonable request with respect to timing of delivery, Horizon promptly shall
(a) provide to AstraZeneca, at AstraZeneca’s cost and expense, copies of the Horizon Regulatory Documentation solely for purposes of exercising AstraZeneca’s and its Affiliates’ rights under the grants in Section 2.3 and
(b) provide to AstraZeneca and to any specified Governmental Authority in the AstraZeneca Territory a letter, in the form reasonably requested by AstraZeneca, acknowledging that AstraZeneca has the right of reference to any Horizon Regulatory
Documentation as described under Section 2.3.3. Notwithstanding anything to the contrary contained in this Agreement, Horizon shall not be required to disclose any information contained in the Horizon Regulatory Documentation or provide any
such access to such information if such disclosure or access would, in Horizon’s reasonable discretion, (x) violate (i) applicable Law or (ii) any binding agreement entered into by Horizon prior to the Effective Date, including
any confidentiality agreement to which Horizon is a party (provided, that Horizon shall use commercially reasonable efforts to obtain consent from any Third Party to any such binding agreement to enable Horizon to disclose such information),
(y) jeopardize any attorney/client privilege or other established legal privilege or (z) disclose any  

  
  

	***	Confidential Treatment Requested 

 - 14 - 

 
trade secrets; provided, that Horizon shall provide AstraZeneca with a general description of the type of any such information redacted or withheld by Horizon to the extent that
Horizon is permitted to do so and keep AstraZeneca informed of all efforts undertaken by Horizon to enable Horizon to disclose such redacted or withheld information to AstraZeneca. 

4.3 Pharmacovigilance Obligations. 
 4.3.1 Safety Data Exchange Agreement. Each Party shall duly and punctually perform all of its obligations under the Safety Data Exchange Agreement. 

4.3.2 Safety Database. AstraZeneca shall set up, hold, and maintain (at AstraZeneca’s sole cost and expense) the global
safety database for the Product and the Other Products. Each Party shall use commercially reasonable efforts to provide the other Party with information in its possession and control as necessary for each Party to comply with its pharmacovigilance
responsibilities under this Agreement or the Safety Data Exchange Agreement, including, as applicable, any Adverse Events, from pre-clinical or clinical laboratory, animal toxicology and pharmacology studies, clinical studies, and commercial
experiences with the Product or any Other Product in the format specified in the Safety Data Exchange Agreement. 
 4.3.3 Esomeprazole Safety Data. Notwithstanding anything to the contrary in this Agreement, if Horizon is required by applicable Law to make any statements in an Adverse Event report or serious
Adverse Event report pertaining to [...***...] of [...***...] and [...***...] the [...***...] to [...***...].

 4.3.4 Medical and Other Inquiries. Except to the extent otherwise provided in this Agreement, the Asset Purchase
Agreement (including the Transition Plan) or the Supply Agreement, from and after the Effective Date, Horizon (a) shall be responsible for, and shall handle and respond to, all customer complaints and inquiries (including medical and
non-medical inquiries) related to the Product or any Other Product used, marketed, distributed or sold in the Horizon Territory, and (b) shall be responsible for, and shall conduct, all correspondence and communication with physicians and other
health care professionals in the Horizon Territory relating to the Product or any Other Product. 
 4.4 Post-Closing
Responsibility for Product. [...***...] shall not [...***...] without the prior written consent of [...***...], such consent not to be unreasonably conditioned, withheld or delayed, if [...***...] in the [...***...]. 

  
  

	***	Confidential Treatment Requested 

 - 15 - 

 ARTICLE 5 
 RECORDS 
 5.1 Records. Horizon shall, and shall cause its
Affiliates and its and their respective Sublicensees to, keep complete and accurate financial books and records pertaining to the commercialization of Merck Products in the Horizon Territory, including books and records of Merck Net Sales of Merck
Products, in sufficient detail to determine, calculate and verify Merck Net Sales of Merck Products in the Horizon Territory and the net present value of the projected Merck Net Sales of Merck Products in the Horizon Territory, in each case, from
the Effective Date until AstraZeneca provides Horizon written notice that Horizon is no longer obligated to maintain such books and records. From and after the date set forth in such written notice, Horizon shall no longer be obligated to maintain
financial books and records pertaining to the commercialization of Merck Products pursuant to this Section 5.1 and AstraZeneca (or its designee) shall no longer have the right to audit and examine Horizon’s financial books and records
pursuant to Section 5.2. Horizon shall and shall cause its Affiliates and its and their respective Sublicensees to, retain such books and records under this Section 5.1 until the date AstraZeneca provides Horizon written notice that
Horizon is no longer obligated to maintain such books and record. In the event that AstraZeneca no longer has any record keeping or reporting obligations to any Merck Party with respect to sales of Merck Products in the Horizon Territory,
AstraZeneca shall promptly notify Horizon in writing, and Horizon’s obligations under this Section 5.1 shall automatically terminate effective upon the termination of such obligations of AstraZeneca to the Merck Parties. 

5.2 Review of Horizon Financial Records. At the request of AstraZeneca, Horizon shall, and shall cause its Affiliates and
its and their respective Sublicensees to, permit AstraZeneca (or its designee) or an independent auditor designated by AstraZeneca (or its designee), at reasonable times and upon reasonable notice, to audit and examine, and make copies or extracts
of and from, the books, records and accounts of Horizon maintained pursuant to Section 5.1 for the purposes set forth in Section 5.1. As between the Parties, the cost of any such review or audit shall be borne by AstraZeneca. In the event
that a Merck Party no longer has any right to audit, and AstraZeneca no longer has any obligation to audit, the books, records and accounts of Horizon maintained pursuant to Section 5.1, AstraZeneca shall promptly notify Horizon in writing, and
AstraZeneca’s (including its designees’ and its or their independent auditors’) rights, and Horizon’s obligations, under this Section 5.2 shall automatically terminate, in each case, effective upon the termination of such
rights of the Merck Parties or obligations of AstraZeneca to the Merck Parties. 
 ARTICLE 6 

ASTRAZENECA PATENTS 
 6.1 Maintenance and Prosecution of AstraZeneca Patents. AstraZeneca shall have the sole right, but not the obligation, to prepare, file, prosecute and maintain (including with respect to
related interference, re-issuance, re-examination, patent term extensions and opposition proceedings) the Merck Patents, the Ex-US Licensed Patents and any other Patent Rights included in the Manufacturing Technology (the “AstraZeneca
Patents”), at AstraZeneca’s sole cost and expense. Horizon shall have no right to prepare, file, prosecute or maintain any AstraZeneca Patents. Horizon shall assist and cooperate with AstraZeneca as

  
 - 16 -

 
AstraZeneca may reasonably request from time to time in connection with its activities set forth in this Section 6.1, at AstraZeneca’s sole cost and expense. Neither AstraZeneca nor any
of its Representatives shall be liable to Horizon in respect of any act, omission, default or neglect on the part of any such Representative in connection with obtaining, prosecuting or maintaining an AstraZeneca Patent or otherwise exercising its
rights under this Section 6.1. AstraZeneca will keep Horizon promptly informed of progress with regard to the preparation, filing, prosecution and maintenance of AstraZeneca Patents in the Horizon Territory. 

6.2 Enforcement of AstraZeneca Patents. 
 6.2.1 Notice. If any AstraZeneca Patent is allegedly or actually infringed by a Third Party in a manner relating to the Product or any Other Product, the Party first having knowledge of such
infringement shall promptly notify the other in writing, which notice shall set forth the facts of that infringement in reasonable detail. 
 6.2.2 AstraZeneca Patents. Subject to this Section 6.2.2, AstraZeneca shall have the sole right, but not the obligation, through counsel of its choosing, to control the prosecution of any
infringement described in Section 6.2.1 relating to the AstraZeneca Patents[...***...]. Prior to
commencing any prosecution of an infringement claim with respect to the AstraZeneca Patents hereunder, AstraZeneca shall notify Horizon of its intent to commence such prosecution, and if Horizon in good faith believes that the prosecution of any
such infringement of the AstraZeneca Patents by AstraZeneca could have a material adverse effect on the AstraZeneca Patents in the Horizon Territory or Horizon’s rights thereunder, Horizon shall promptly notify AstraZeneca after receiving such
notice of intent and the Parties shall discuss in good faith the appropriate actions to be taken in response to such infringement; provided, however, that if the Parties are unable to come to a mutually acceptable resolution, then AstraZeneca
shall be entitled to undertake such prosecution in its sole discretion, taking Horizon’s concerns into good faith consideration. Horizon shall have no right to prosecute any infringement of any AstraZeneca Patents. 

6.2.3 Enforcement Procedure; Costs and Recovery. If AstraZeneca brings an infringement action in accordance with this
Section 6.2, Horizon shall cooperate fully with AstraZeneca in connection therewith, including furnishing powers of attorney, being joined as a party plaintiff in such action, providing access to relevant documents and other evidence and making
its employees available at reasonable business hours, at AstraZeneca’s sole cost and expense. If AstraZeneca pursues such an infringement action, it shall consider in good faith any comments from Horizon and shall keep Horizon reasonably
informed of any steps taken to preclude such infringement. Each Party shall bear its own costs and expenses relating to any enforcement action commenced pursuant to this Section 6.2. Any damages or other amounts collected shall be first
allocated to reimburse the Parties for their costs and expenses in enforcing 

  
  

	***	Confidential Treatment Requested 

 - 17 - 

 
the AstraZeneca Patents in order to make such recovery, which amounts shall be allocated pro rata based on the relative costs and expenses incurred by the Parties in connection with such
enforcement if insufficient to cover the totality of such expenses. Any amount of recovery remaining after such reimbursement is made shall be retained by AstraZeneca. 
 6.3 Infringement Claims by Third Parties. 
 6.3.1 Defense of
Third Party Claims. If a Third Party asserts that a Patent Rights or other intellectual property right (other than Trademarks or Domain Names, which shall be governed by Sections 7.4 and 8.5, respectively) owned or controlled by it is infringed
by the Manufacture or Exploitation of the Product or any Other Product, the Party first obtaining knowledge of such a claim shall immediately provide the other Party notice of such claim along with the related facts in reasonable detail. 

6.3.2 Horizon Territory. Horizon shall have the first right, but not the obligation, to control the defense of any claim described
in Section 6.3.1 to the extent it relates to the Manufacture or Exploitation of the Product or any Other Product in the Horizon Territory; provided that Horizon shall not be entitled to assert a claim or counterclaim against such Third
Party based on the AstraZeneca Patents in connection therewith without AstraZeneca’s prior written consent, in its sole discretion; and, provided, further, that prior to commencing any such claim or counterclaim hereunder, Horizon shall
notify AstraZeneca of its intent to commence such claim or counterclaim, and if AstraZeneca in good faith believes that the assertion of any such claim or counterclaim by Horizon could have a material adverse effect on the AstraZeneca Patents in the
AstraZeneca Territory or AstraZeneca’s rights thereunder or the Nexium Business, AstraZeneca shall promptly notify Horizon after receipt of such notice of intent and the Parties shall discuss in good faith the appropriate actions to be taken in
response to such claim. 
 6.3.3 AstraZeneca Territory. AstraZeneca shall have the sole right, but not the obligation, to
control the defense of any claim described in Section 6.3.1 to the extent it relates to the Manufacture or Exploitation of the Product or any Other Product in the AstraZeneca Territory. 

6.3.4 Defense Procedure. The Party that does not control the defense of a claim under this Section 6.3 shall cooperate with
the controlling Party, at the controlling Party’s reasonable request and expense, in any such defense and shall have the right, at its own expense, to be represented separately by counsel of its own choice in any such proceeding. If a Party is
entitled to and brings a claim or counterclaim in accordance with this Section 6.3, the other Party shall cooperate fully with the claiming Party in connection therewith, including furnishing powers of attorney, being joined as a party
plaintiff in such action, providing access to relevant documents and other evidence and making its employees available at reasonable business hours. In connection with any such defense or claim or counterclaim, the controlling Party shall consider
in good faith any comments from the other Party and shall keep the other Party reasonably informed of any steps taken in connection with such defense, claim or counterclaim. 
 6.3.5 Settlement of Third Party Claims. The Party that controls the defense of a given claim pursuant to Section 6.3.2 or 6.3.3 also shall have the right to control

  
 - 18 -

 
settlement of such claim; provided, however, that (a) no settlement shall be entered into without the prior written consent of the other Party if such settlement would
adversely affect or diminish the rights and benefits of the other Party under this Agreement, or impose any new obligations or adversely affect any obligations of the other Party under this Agreement and (b) in connection with any such
settlement, if Horizon is the controlling Party, unless otherwise agreed in writing by AstraZeneca, Horizon shall only be entitled to grant a license or covenant not to sue under or with respect to the AstraZeneca Patents or Licensed Know-How, as
applicable, to the extent provided in Section 2.2.  
 6.3.6 Allocation of Costs. All costs and expenses
relating to any defense, settlement and judgments in Litigation commenced pursuant to this Section 6.3 with respect to (a) the Horizon Territory shall be borne by the Party controlling such Litigation in accordance with this Article 6 and
(b) in the AstraZeneca Territory shall be borne by AstraZeneca. Any damages or other amounts collected shall be first allocated to reimburse the financially responsible Party (as set forth in the immediately preceding sentence) for its costs
and expenses in making such recovery. Any amount of recovery remaining after such reimbursement is made shall be retained by the controlling Party under this Section 6.3. 
 6.4 Invalidity or Unenforceability Defenses or Actions. If a Third Party asserts, as a defense or as a counterclaim in any infringement action under Section 6.2 or claim or counterclaim
asserted under Section 6.3, or in a declaratory judgment action or similar action or claim filed by such Third Party, in any such case, that any AstraZeneca Patent is invalid or unenforceable, then the Party pursuing such infringement action,
or the Party first obtaining knowledge of such declaratory judgment action, as the case may be, shall promptly give written notice to the other Party. AstraZeneca shall have the sole right, but not the obligation, through counsel of its choosing, to
defend against such action or claim. If AstraZeneca defends such action or claim, all costs and expenses of defending such action or claim shall be borne by AstraZeneca. Horizon shall assist and cooperate with AstraZeneca as AstraZeneca may
reasonably request from time to time in connection with its activities set forth in this Section 6.4, including by providing access to relevant documents and other evidence and making its employees available at reasonable business hours, at
AstraZeneca’s sole cost and expense. In connection with any such defense or claim or counterclaim, AstraZeneca shall consider in good faith any comments from Horizon and shall keep Horizon reasonably informed of any steps taken, and shall
provide copies of all documents filed, in connection with such defense, claim or counterclaim. 
 6.5 Statements or Actions
Pertaining to Esomeprazole or Nexium. Notwithstanding anything to the contrary in this Article 6, [...***...] of [...***...] or [...***...] of its [...***...] or [...***...] of the [...***...]. 

  
  

	***	Confidential Treatment Requested 

 - 19 - 

 ARTICLE 7 
 LICENSED TRADEMARKS 
 7.1 Use of Licensed Trademarks.

 7.1.1 Horizon hereby acknowledges AstraZeneca’s exclusive right, title and interest in and to the Licensed Trademarks,
together with all goodwill associated therewith and all registrations and registration applications therefor, on a worldwide basis and acknowledges that nothing herein shall be construed to accord to Horizon or its Affiliates any rights in the
Licensed Trademarks except for the license rights expressly conferred by this Agreement. Horizon shall not, and shall cause its Affiliates, Sublicensees and distributors not to, use in their respective businesses, any Trademark that is confusingly
similar to or a colorable imitation of, misleading or deceptive with respect to or that dilutes any (or any part) of the Licensed Trademarks. 
 7.1.2 Horizon shall, and shall cause its Affiliates, Sublicensees and distributors to, (a) comply with all trademark usage guidelines, quality standards, business practices, methodology, policies and
procedures and technical and operational specifications as may be reasonably specified by AstraZeneca from time to time or as may be imposed by applicable Law with respect to the manner of use of the Licensed Trademarks[...***...], (b) promptly make any changes to any Product Label, packaging with respect to any Product or any
Other Product, Product (or any Other Product) inserts and advertising, marketing, promotional or other materials bearing any of the Licensed Trademarks as AstraZeneca may reasonably request to achieve compliance with clause (a), and (c) refrain
from taking any action that endangers, destroys or similarly affects, in any material respect, the Licensed Trademarks or the value of the goodwill associated with the Licensed Trademarks. 

7.1.3 Horizon shall not, and shall cause its Affiliates, Sublicensees and distributors not to, (a) directly or indirectly, at any
time challenge AstraZeneca’s rights, title or interest in and to the Licensed Trademarks or in any registration or registration application therefor in any jurisdiction, (b) do or cause to be done or fail to do anything, the doing, causing
or failure of which would contest or impair or in any way tend to impair the rights of AstraZeneca in and to the Licensed Trademarks or in any registrations or registration applications therefor in any jurisdiction, (c) represent to any Third
Party that it has, in any jurisdiction, any ownership rights in or to the Licensed Trademarks or in any registration or registration application therefor or any other rights in the Licensed Trademarks other than the specific license rights conferred
by this Agreement, or (d) register or attempt to register the Licensed Trademarks or any confusingly similar Trademark (including any translation or transliteration of any of the Licensed Trademarks or any colorable imitation thereof) as a
Trademark with any Governmental Authority in its own name or in the name of any of its Affiliate or any Third Party in any jurisdiction. 

  
  

	***	Confidential Treatment Requested 

 - 20 - 

 7.1.4 Horizon acknowledges and agrees that no ownership rights are vested or created in the
Licensed Trademarks anywhere in the world by the licenses and other rights granted in this Agreement (including, for clarity, under Section 2.1 of this Agreement) and that all goodwill generated in connection with the use of the Licensed
Trademarks by Horizon, its Affiliates, Sublicensees, and distributors shall inure solely for and to the benefit of AstraZeneca. 

7.2 Approval Procedures. 
 7.2.1 During the Term, if Horizon desires to use any variation or derivative of an existing Licensed Trademark on, or in connection with the Exploitation of, the Product or any Other Product in the
Horizon Territory, Horizon shall submit such variation or derivation to AstraZeneca for its approval, which approval may be granted or withheld in AstraZeneca’s sole discretion. If AstraZeneca approves such variation or derivation, then upon
such approval by AstraZeneca, such variation or derivation shall be deemed a Licensed Trademark and subject to the terms hereof. AstraZeneca shall respond to each such submission within [...***...] after AstraZeneca’s receipt of each such request for approval. With respect to any variation or derivation of any existing Licensed Trademark that
Horizon submits to AstraZeneca, Horizon shall be responsible for conducting a commercially reasonable trademark clearance search and assessing the availability of any such variation or derivation for use on, and registration for, the Product or any
Other Product in the Horizon Territory and shall submit the results of such search and assessment to AstraZeneca when it submits such variation or derivation to AstraZeneca for its approval. 

7.2.2 At AstraZeneca’s reasonable request with respect to timing of delivery, Horizon shall, and shall cause its Affiliates,
Sublicensees and distributors to, furnish to AstraZeneca representative samples of all goods and all Product Labeling, Product packaging, Product inserts and advertising, marketing, promotional or other materials bearing any of the Licensed
Trademarks for registration, renewal and quality control purposes, including web pages, brochures and stationery. 
 7.3
Clearance, Registration, Prosecution and Maintenance of Licensed Trademarks. 
 7.3.1 AstraZeneca shall be
responsible for the registration, prosecution and maintenance of the Licensed Trademarks in the Horizon Territory. All registrations and applications therefor shall be filed, prosecuted, registered and maintained in the name, and for the benefit, of
AstraZeneca. All costs and expenses of clearing, registering, prosecuting and maintaining the Licensed Trademarks in the Horizon Territory shall be borne solely by AstraZeneca. AstraZeneca shall (a) provide Horizon from time to time[...***...]
a written report summarizing the current status of all applications and registrations for the Licensed Trademarks in the Horizon Territory; (b) notify Horizon promptly of, and consult with Horizon with respect to, any material, substantive
issue or any opposition, cancellation, invalidity or other proceeding that may be raised or asserted against any application or registration for any Licensed Trademark within the Horizon Territory prior to taking any action in response thereto; and
(c) consult with Horizon at least [...***...] prior to (i) taking any action to abandon or withdraw any application for any Licensed Trademark, or (ii)

  
  

	***	Confidential Treatment Requested 

 - 21 - 

 
permitting any registration for any Licensed Trademark to lapse, expire or be cancelled. 
 7.3.2 If AstraZeneca plans to cease, or ceases, the registration, prosecution and maintenance of a Licensed Trademark in the Horizon Territory, AstraZeneca shall notify Horizon in writing at least [...***...] in advance of the due date of any action that is required with respect thereto and, in such event, Horizon
may elect (but shall not be obligated), on written notice to AstraZeneca, at its sole cost and expense, to assume responsibility for and control over such registration, prosecution and maintenance in the name of Horizon. All registrations and
applications therefor shall be filed, prosecuted, registered and maintained in the name, and for the benefit, of Horizon. AstraZeneca shall execute such powers of attorney or other instruments and shall take such other actions as Horizon may
reasonably request to permit Horizon to file and prosecute any registration application and to maintain, renew, enforce and defend any registration for any such Licensed Trademarks in the Horizon Territory. 

7.4 Enforcement and Defense of Licensed Trademarks. Horizon shall have the first right, but not the obligation, to enforce
and defend the Licensed Trademarks in the Horizon Territory, including (a) after consultation with AstraZeneca, defending against any alleged, threatened or actual claim by a Third Party that the use of the Licensed Trademarks in the Horizon
Territory infringes, dilutes, misappropriates or otherwise violates any Trademark or copyright of that Third Party or constitutes unfair trade practices or any other like offense, or any other claims as may be brought by a Third Party against a
Party in connection with the use of or relating to the Licensed Trademarks with respect to the Product or any Other Product in the Horizon Territory and (b) taking such action as Horizon, after consultation with AstraZeneca, deems necessary
against a Third Party based on any alleged, threatened or actual infringement, dilution, misappropriation or other violation of, or unfair trade practices or any other like offense relating to, the Licensed Trademarks by a Third Party in the Horizon
Territory; provided that if Horizon plans to cease, or ceases, any action with respect to the enforcement or defense of any of the Licensed Trademarks in the Horizon Territory, Horizon shall notify AstraZeneca in writing at least [...***...]
in advance of the due date of any action that is required with respect thereto and, in such event, AstraZeneca may elect (but shall not be obligated), on written notice to Horizon, to assume responsibility for and control over such enforcement or
defense or to take any such action in its own name or in the name of Horizon. Notwithstanding the foregoing, as long as Horizon is Exploiting the Product or any Other Product under the Licensed Trademarks, if Horizon reasonably determines that
initiating a suit or taking other action to enforce or defend any of the Licensed Trademarks in the Horizon Territory pursuant to this Section 7.4 is not in the best interests of the Licensed Trademarks in the Horizon Territory and Horizon so
notifies AstraZeneca in writing (which notice shall include a reasonably detailed description of Horizon’s reasons for not initiating suit or taking other action to enforce or defend any of the Licensed Trademarks in the Horizon Territory
pursuant to this Section 7.4), then AstraZeneca may not enforce or defend any such Licensed Trademarks pursuant to this Section 7.4. Each enforcing or defending Party shall bear its own costs and expenses relating to any enforcement action
or defense commenced pursuant to this Section 7.4 and any settlements and judgments with respect thereto. Any damages or other amounts recovered in any such proceeding shall be retained by the Party controlling such proceeding. Each Party shall
provide to the other Party all reasonable assistance requested by the other Party in connection with any such action, defense, claim or suit under this Section 7.4, at such other Party’s cost and expense. Horizon shall obtain

  
  

	***	Confidential Treatment Requested 

 - 22 - 

 
AstraZeneca’s written consent before entering into any compromise, settlement or stipulation with respect to any such action, defense, claim or suit (such consent not to be unreasonably
withheld or delayed). In no event shall Horizon take any position or submit any argument with respect to such action, defense, claim or suit that would be reasonably expected to materially endanger, lessen, impair or undermine the Licensed
Trademarks or AstraZeneca’s rights therein or AstraZeneca’s corresponding Trademark rights outside the Horizon Territory. Each Party, at the other Party’s cost and expense, shall execute such powers of attorney or other instruments
and shall take such other actions as the other Party may reasonably request as necessary to permit the other Party to assume responsibility for and control over the enforcement or defense of the Licensed Trademarks as permitted hereunder.

 7.5 No Implied Rights. Except as expressly provided in this Article 7, Horizon shall have no right to register,
maintain, prosecute, enforce or defend the Licensed Trademarks. 
 7.6 Other Trademarks. Horizon shall have the right to
Exploit the Product and any Other Product in the Horizon Territory under a Trademark that is not a Licensed Trademark; provided, that such other Trademark is not confusingly similar to any Licensed Trademark (including any translation or
transliteration of any Licensed Trademark or any colorable imitation of any Licensed Trademark). 
 ARTICLE 8 

LICENSED DOMAIN NAMES 
 8.1 Ownership and Goodwill. Horizon acknowledges that it acquires no right, title or interest in the Licensed Domain Names other than the rights expressly set forth in this Agreement.
Horizon shall not at any time do or suffer to be done any act that would materially impair AstraZeneca’s proprietary rights in or to the Licensed Domain Names, and Horizon agrees not to directly or indirectly contest or aid in contesting the
ownership of the Licensed Domain Names, or to take any action whatsoever in derogation of AstraZeneca’s claimed rights therein. Horizon agrees and acknowledges that any and all rights and goodwill arising from use of the Licensed Domain Names
by Horizon or its Affiliates or permitted sublicensees shall inure exclusively to the benefit of AstraZeneca. 
 8.2
Registration and Maintenance. AstraZeneca shall (a) at its own expense, maintain the Primary Licensed Domain Name and (b) if requested in writing by Horizon and at Horizon’s expense, maintain the Secondary Licensed
Domain Names. Neither Party shall intentionally take, or fail to take, any action that may reasonably be expected to jeopardize the use, value, validity, or enforceability of any Licensed Domain Name; provided, that unless Horizon requests in
writing that AstraZeneca maintain a Secondary Licensed Domain Name at Horizon’s expense, AstraZeneca may allow the registration for such Secondary Licensed Domain Name to lapse. 

8.3 Control of Licensed Domain Name Websites. AstraZeneca hereby grants Horizon the sole right to administer, manage and
control the content of any website associated with, and use, the Licensed Domain Names (the “Product Websites”) under the terms of this Agreement. At Horizon’s request, AstraZeneca shall use the technical contact and

  
 - 23 -

 
server information provided by Horizon for the Licensed Domain Names. Horizon may ask from time to time that such information be further revised or updated, and AstraZeneca shall, within a
reasonable amount of time, contact the domain name registrar and revise the information accordingly. AstraZeneca shall not change the technical contact or server information for the Licensed Domain Names or take any action to direct Internet traffic
to any of the Licensed Domain Names to any servers or IP addresses other than those identified by Horizon. AstraZeneca may, from time to time, change the registrar with whom AstraZeneca has contracted to manage its domain name portfolio. Horizon
shall assist and cooperate with AstraZeneca, the old registrar or the new registrar in any way necessary to effectuate such a change of registrar. Horizon shall be responsible for the content of the Product Websites and shall ensure that all Product
Websites comply with all applicable Law. 
 8.4 Country-Specific Traffic. 

8.4.1 Horizon shall use commercially reasonable efforts to cause traffic to the Licensed Domain Names that originates within a country
outside the Horizon Territory, to be re-directed to such ccTLD as AstraZeneca may designate in writing. 
 8.4.2 AstraZeneca
shall use commercially reasonable efforts to cause traffic to vimovoglobal.com, or any other Domain Name used by or on behalf of AstraZeneca or its Affiliates in connection with Exploitation of the Products in more than one country of the
AstraZeneca Territory, that originates within a country outside the AstraZeneca Territory, to be re-directed to such ccTLD as Horizon may designate in writing. 
 8.4.3 Among other techniques that the Parties may mutually agree for re-directing traffic is the placement of a hyperlink on the homepage of the generic “.com” top-level Licensed Domain Names or
other domain names noted in Section 8.4.2, as applicable, which hyperlink shall be placed in a manner, form and style mutually agreeable to the Parties. 
 8.5 Enforcement. If Horizon becomes aware of any use, trafficking, or registration of a Licensed Domain Name other than by or on behalf of Horizon or its Affiliates or Sublicensees pursuant to this
Agreement or of any use, trafficking, or registration a confusingly similar domain name, Horizon shall promptly notify AstraZeneca of such use or trafficking or registration. AstraZeneca may take any action and institute legal, administrative or
other proceedings relating to the use, trafficking, or registration of such Licensed Domain Names as AstraZeneca, in its sole discretion, deems fit. Horizon shall execute any and all documents and to do such acts as may be reasonably necessary to
carry out such proceeding or Litigation, including becoming a nominal party to any legal action. If AstraZeneca fails to take any action within [...***...] days after notification of such use, trafficking or registration, or notifies Horizon that it
will not take any action, then Horizon may take any action and institute legal, administrative or other proceedings relating to such use, trafficking or registration as Horizon, in its sole discretion, deems appropriate. AstraZeneca agrees to
execute any and all documents and to do such acts as may be reasonably necessary to carry out such proceeding or Litigation, including becoming a nominal party to any legal action. Each Party shall bear its own costs and expenses relating to any
enforcement action commenced pursuant to this Section 8.5 and any settlements and judgments with respect thereto. 

  
  

	***	Confidential Treatment Requested 

 - 24 - 

 ARTICLE 9 
 CONFIDENTIALITY AND NON-DISCLOSURE 
 9.1 General. 

 9.1.1 All Ancillary Confidential Information provided by one Party (or its Recipients or Affiliates) (collectively,
the “Ancillary Disclosing Party”) to the other Party (or its Recipients or Affiliates) (collectively, the “Ancillary Receiving Party”) shall be subject to and treated in accordance with the terms of this
Section 9.1. As used in this Section 9.1, “Ancillary Confidential Information” means (a) all information disclosed to the Ancillary Receiving Party by the Ancillary Disclosing Party in connection with any Ancillary
Agreement, including all information with respect to the Ancillary Disclosing Party’s licensors, licensees or Affiliates and (b) all memoranda, notes, analyses, compilations, studies and other materials prepared by or for the Ancillary
Receiving Party to the extent containing or reflecting the information in the preceding clause (a). Notwithstanding the foregoing, Ancillary Confidential Information shall not include information that, in each case as demonstrated by competent
written documentation: 
 (a) was already known to the Ancillary Receiving Party or its Affiliates, other than under an
obligation of confidentiality, at the time of disclosure by the Ancillary Disclosing Party; 
 (b) was generally available to
the public or otherwise part of the public domain at the time of its disclosure to the Ancillary Receiving Party; 
 (c) became
generally available to the public or otherwise part of the public domain after its disclosure to the Ancillary Receiving Party other than through any act or omission of the Ancillary Receiving Party in breach of this Agreement; 

(d) is subsequently disclosed to the Ancillary Receiving Party by a Third Party without obligations of confidentiality with respect
thereto; or 
 (e) is subsequently independently discovered or developed by the Ancillary Receiving Party without the aid,
application or use of Confidential Information or Ancillary Confidential Information. 
 9.1.2 All Ancillary
Confidential Information obtained by AstraZeneca (or its Affiliates or Recipients) from Horizon (or its Affiliates or Recipients) and all Ancillary Confidential Information relating solely to the Product Business (other than Ancillary Confidential
Information relating to (x) the Licensed Intellectual Property, the Ex-US Licensed Patents or the Licensed Regulatory Documentation, (y) the Pozen Original Agreement or the Pozen ROW Agreement or (z) the Merck Parties or the Merck
Patents), the Purchased Assets and the Assumed Liabilities (the “Ancillary Horizon Confidential Information”) shall be deemed to be Ancillary Confidential Information disclosed by Horizon to AstraZeneca for purposes of this
Section 9.1 and shall be used by AstraZeneca solely as required for any AstraZeneca Permitted Purpose, and for no other purpose. During the Term and for a period of five years thereafter, AstraZeneca shall not disclose, or permit the disclosure
of, any of the Ancillary  

  
 - 25 -

 
Horizon Confidential Information to any Person except those Persons to whom such disclosure is necessary in connection with any AstraZeneca Permitted Purpose. AstraZeneca shall treat, and will
cause its Affiliates and the Recipients of AstraZeneca or any of its Affiliates to treat, the Ancillary Horizon Confidential Information as confidential, using the same degree of care as AstraZeneca normally employs to safeguard its own confidential
information from unauthorized use or disclosure, but in no event less than a reasonable degree of care. 
 9.1.3 All
Ancillary Confidential Information obtained by Horizon (or its Affiliates or Recipients) from AstraZeneca (or its Affiliates or Recipients) other than the Ancillary Horizon Confidential Information (the “Ancillary AstraZeneca Confidential
Information”) shall be used by Horizon solely as required for any Horizon Permitted Purpose, and for no other purpose. During the Term and for a period of five years thereafter, Horizon shall not disclose, or permit the disclosure of, any
of the Ancillary AstraZeneca Confidential Information to any Person except (x) those Persons to whom such disclosure is necessary in connection with a Horizon Permitted Purpose or (y) in connection with any due diligence or disclosure
obligations under any financing arrangement or equity offering pursuant to obligations of confidentiality and non-use no less stringent than those set forth in this Section 9.1. Horizon shall treat, and will cause its Affiliates and the
Recipients of Horizon or any of its Affiliates to treat, Ancillary AstraZeneca Confidential Information as confidential, using the same degree of care as Horizon normally employs to safeguard its own confidential information from unauthorized use or
disclosure, but in no event less than a reasonable degree of care. 
 9.1.4 In the event either Party is requested
pursuant to, or required by, applicable Law to disclose any of the other Party’s Ancillary Confidential Information (i.e., Ancillary AstraZeneca Confidential Information or Ancillary Horizon Confidential Information, as applicable), it will
notify the other Party in a timely manner so that such Party may seek a protective order or other appropriate remedy or, in such Party’s sole discretion, waive compliance with the confidentiality provisions of this Agreement. Each Party will
cooperate in all reasonable respects in connection with any reasonable actions to be taken for the foregoing purpose. In any event, the Party requested or required to disclose such Ancillary Confidential Information may furnish it as requested or
required pursuant to applicable Law (subject to any such protective order or other appropriate remedy) without liability hereunder, provided that such Party furnishes only that portion of the Ancillary Confidential Information which such Party is
advised by an opinion of its counsel is legally required and such Party exercises reasonable efforts to obtain reliable assurances that confidential treatment will be accorded such Ancillary Confidential Information. 

9.1.5 Nothing in this Section 9.1 shall be construed as preventing or in any way inhibiting either Party from complying with
applicable Law governing activities and obligations undertaken pursuant to this Agreement, the Asset Purchase Agreement or any other Ancillary Agreement in any manner which it reasonably deems appropriate. 

9.2 Other Nexium Communications. Except as expressly provided in Sections 4.1.2, 4.3.4 and 9.3 hereof, the Asset Purchase
Agreement or any Ancillary Agreement, without [...***...] prior written consent, [...***...] shall not make, and shall prohibit its Affiliates, Sublicensees, Third Party contractors, and agents from [...***...] or [...***...]

  
  

	***	Confidential Treatment Requested 

 - 26 - 

 
[...***...]. 
 9.3 Certain Permitted Esomeprazole and Nexium
Disclosures. Within 30 days after the Effective Date, the Parties shall mutually agree in good faith on a written document specifying [...***...], and the [...***...] to be [...***...] that is not [...***...]. 

9.4 Press Releases. [...***...] to the [...***...]. 

ARTICLE 10 

DISCLAIMER OF WARRANTIES 

EACH PARTY ACKNOWLEDGES AND AGREES THAT, EXCEPT FOR THE EXPRESS REPRESENTATIONS AND WARRANTIES CONTAINED IN THE ASSET PURCHASE AGREEMENT OR THE SUPPLY
AGREEMENT, THE OTHER PARTY HAS MADE NO REPRESENTATION OR WARRANTY WHATSOEVER AND SUCH PARTY HAS NOT RELIED ON ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, INCLUDING ANY WARRANTY
OF QUALITY, FITNESS FOR A PARTICULAR PURPOSE, MERCHANTABILITY, CONDITION OF THE ASSETS, AS TO THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF ANY PERSON OR AS TO ANY OTHER MATTER IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY.

 ARTICLE 11 
 INDEMNITY 
 11.1 Indemnification of AstraZeneca.
Subject to this Article 11, Horizon shall indemnify, defend and hold harmless AstraZeneca and its Affiliates, and their respective officers, directors, employees and agents (collectively, “AstraZeneca Indemnitees”) from and
against any and all Losses incurred by them in connection with any and all Litigation by Third Parties (collectively, “Third Party Claims”) arising from or occurring as a result of: (a) any breach by Horizon of any term of this
Agreement; (b) the fraud, gross negligence or willful misconduct on the part of any Horizon Indemnitees in the performance of Horizon’s obligations under this Agreement or (c) the Manufacture or Exploitation of the Product or any
Other Product by or on behalf of Horizon, its Affiliates and Sublicensees (but excluding the Manufacture or Exploitation of Product or any Other Product by or on behalf of AstraZeneca or its Affiliates pursuant to the Supply Agreement, the
Transition Plan (as defined in the Asset Purchase Agreement) or pursuant to any sublicense granted by Horizon to AstraZeneca under the this Agreement or any Ancillary Agreement), except, in each case ((a), (b) and (c)), to the extent of 

  
  

	***	Confidential Treatment Requested 

 - 27 - 

 
those Losses for which AstraZeneca has an obligation to indemnify any Horizon Indemnitees pursuant to Section 11.2 or pursuant to the Supply Agreement or the Asset Purchase Agreement, as to
which Losses each Party shall indemnify the other Party and the AstraZeneca Indemnitees or the Horizon Indemnitees, as applicable, to the extent of its liability for such Losses. 

11.2 Indemnification of Horizon. Subject to this Article 11, AstraZeneca shall indemnify, defend and hold harmless Horizon
and its Affiliates, and their respective officers, directors, employees and agents (collectively, “Horizon Indemnitees”) from and against any and all Losses incurred by them in connection with any and all Third Party Claims arising
from or occurring as a result of: (a) any breach by AstraZeneca of any term of this Agreement; (b) the fraud, gross negligence or willful misconduct on the part of any AstraZeneca Indemnitees in the performance of AstraZeneca’s
obligations under this Agreement; (c) the Manufacture or Exploitation of the Product or any Other Product by or on behalf of AstraZeneca, its Affiliates and sublicensees (but excluding the Manufacture of Product under the Supply Agreement),
except, in each case ((a), (b) and (c)), to the extent of those Losses for which Horizon has an obligation to indemnify any AstraZeneca Indemnitees pursuant to Section 11.1 or pursuant to the Supply Agreement, as to which Losses each Party
shall indemnify the other Party and the AstraZeneca Indemnitees or the Horizon Indemnitees, as applicable, to the extent of its liability for such Losses. 
 11.3 Indemnification Procedures. All indemnification claims in respect of Horizon or any Horizon Indemnitees shall be made solely by Horizon and all indemnification claims in respect of
AstraZeneca or any AstraZeneca Indemnitee shall be made solely by AstraZeneca and, in each case, shall be governed by Section 7.2.2 of the Asset Purchase Agreement. Notwithstanding anything herein to the contrary, the Parties’ respective
indemnification obligations under this Article 11 shall not apply to any Losses for which such Party is entitled to indemnification under the Asset Purchase Agreement (excluding for this purpose, application of the limitations in Section 7.3 of
the Asset Purchase Agreement). 
 11.4 Limitation on Damages and Liability. [...***...] 

11.5 Insurance. As of the Effective Date, Horizon shall have and maintain adequate insurance coverage, which policies shall
be in effect during the Term and shall include products liability coverage and comprehensive general liability insurance of not less than [...***...]; provided that if any such policy is held on a claims-made basis, such policy shall be
maintained throughout the Term and for a period of [...***...] thereafter. All insurers 

  
  

	***	Confidential Treatment Requested 

 - 28 - 

 
providing such policies shall have an AM Best (A-) or higher rating. Horizon shall provide AstraZeneca with certificates of insurance evidencing that the policies required to be maintained by
Horizon hereunder are in full force and effect annually and, upon AstraZeneca’s request, copies of such policies shall be provided. Should any of the policies be cancelled, terminated or otherwise materially altered before the expiration date
thereof, notice will be delivered in accordance with the policy provisions in writing to AstraZeneca. 
 ARTICLE 12

 TERM AND TERMINATION 
 12.1 Term. The term of this Agreement shall commence on the Effective Date and shall continue in full force and effect until terminated in accordance with this Article 12 (such period,
the “Term”). 
 12.2 Termination for Material Breach. In the event that either Party (the
“Breaching Party”) breaches any of its material obligations under Section 2.6, Section 3.3, Section 3.4, Article 7 or Article 8, the other Party may terminate the Terminable Rights and Provisions upon [...***...]
days’ prior written notice (such [...***...]-day period, the “Notice Period”) to the Breaching Party, specifying the breach and its claim of right to terminate; provided, that the termination of the Terminable Rights and
Provisions shall not become effective at the end of the Notice Period if (a) the Breaching Party cures such breach during the Notice Period or (b) such breach cannot be cured during the Notice Period and the Breaching Party commences and
diligently pursues actions to cure such breach within the Notice Period, in which case the Breaching Party shall have an additional [...***...]-day period to cure such breach before such termination becomes effective. 

12.3 Mutual Agreement. This Agreement or the Terminable Rights and Provisions may be terminated upon the mutual written
agreement of Horizon and AstraZeneca at any time. 
 12.4 Consequences of Termination. 

12.4.1 Termination of Terminable Rights and Provisions. Upon any termination of the Terminable Rights and Provisions pursuant to
Section 12.2 or Section 12.3, (a) the licenses granted by AstraZeneca to Horizon under Section 2.1 solely with respect to the Licensed Trademarks and Licensed Domain Names, any sublicenses related thereto entered into by Horizon
pursuant to Section 2.2 and Articles 7 and 8, in each case, at AstraZeneca’s option, shall terminate in their entirety and (b) the licenses granted by AstraZeneca to Horizon under Section 2.1 with respect to the US Licensed
Patents, Ex-US Licensed Patents, Licensed Know-How, Licensed Regulatory Documentation and the Manufacturing Technology, the licenses granted by Horizon to AstraZeneca under Section 2.3 and all other provisions of this Agreement (other than
those provisions referenced in the preceding clause (a)) shall remain in full force and effect. 
 12.4.2 Termination of
Agreement. Upon the termination of this Agreement pursuant to Section 12.3, all of the licenses granted by the Parties under Article 2, and any sublicenses related thereto entered into by either Party as permitted hereunder, and all

  
  

	***	Confidential Treatment Requested 

 - 29 - 

 
other rights and obligations of this Agreement (subject to those rights and obligations that survive as set forth in Section 12.4.5 of this Agreement), shall terminate in their entirety.

 12.4.3 Discontinued Use of Trademarks. Upon any termination described in Section 12.4.1 or Section 12.4.2,
Horizon shall, and shall cause its Affiliates, Sublicensees and distributors to discontinue all use of the Licensed Trademarks (including in connection with all Product Labels, packaging with respect to the Product or any Other Product, Product (or
any Other Product) inserts and advertising, marketing, promotional or other materials bearing any of the Licensed Trademarks) and Licensed Domain Names promptly, but in any event, within 90 days after any such termination. 

12.4.4 Accrued Rights. The termination of this Agreement for any reason shall be without prejudice to any rights that shall have
accrued to the benefit of a Party prior to such termination. Such termination shall not relieve a Party from obligations that are expressly indicated to survive the termination of this Agreement. 

12.4.5 Survival. Without limiting the foregoing, Sections 2.4, 2.5, 5.1 (to the extent required under the Merck Agreements), 5.2
(to the extent required under the Merck Agreements), this Section 12.4 and ARTICLE 9, ARTICLE 10, ARTICLE 11 (provided that Section 11.5 survives only for as long as provided in Section 11.5), and ARTICLE 13 shall survive the
termination of this Agreement for any reason. 
 ARTICLE 13 

MISCELLANEOUS 
 13.1 Governing Law, Jurisdiction, Venue and Service. 
 13.1.1
Governing Law. This Agreement shall be governed by and construed in accordance with the Laws of the State of New York, excluding any conflicts or choice of Law rule or principle that might otherwise refer construction or interpretation of
this Agreement to the substantive Law of another jurisdiction. 
 13.1.2 Jurisdiction. Subject to Section 13.2 and
13.12, the Parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the courts of the State of New York and the United States District Court for the Southern District of New York for any action, suit or proceeding
(other than appeals therefrom) arising out of or relating to this Agreement, and agree not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts. The Parties irrevocably and unconditionally
waive their right to a jury trial. 
 13.1.3 Venue. Subject to Section 13.2 and 13.12, the Parties further hereby
irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the courts of the State of New York or in the United States
District Court for the Southern District of New York, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in
an inconvenient forum. 

  
 - 30 -

 13.1.4 Service. Each Party further agrees that service of any process, summons,
notice or document by registered mail to its address set forth in Section 13.3.2 shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any such court. 

13.2 Dispute Resolution. 
 13.2.1 Except as provided in Section 13.12, if a dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith (a
“Dispute”), then either Party shall have the right to refer such Dispute to the Senior Officers for attempted resolution by good faith negotiations during a period of 10 Business Days. Any final decision mutually agreed to by the
Senior Officers in writing shall be conclusive and binding on the Parties. 
 13.2.2 If such Senior Officers are unable to
resolve any such Dispute within such 10-Business Day period, either Party shall be free to institute binding arbitration in accordance with this Section 13.2.2 upon written notice to the other Party (an “Arbitration Notice”)
and seek such remedies as may be available. Upon receipt of an Arbitration Notice by a Party, the applicable Dispute shall be resolved by final and binding arbitration before a panel of three experts with relevant industry experience (the
“Arbitrators”). Each of Horizon and AstraZeneca shall promptly select one Arbitrator, which selections shall in no event be made later than 30 days after the notice of initiation of arbitration. The third Arbitrator shall be chosen
promptly by mutual agreement of the Arbitrator chosen by Horizon and the Arbitrator chosen by AstraZeneca, but in no event later than 30 days after the date that the last of such Arbitrators was appointed. The Arbitrators shall determine what
discovery will be permitted, consistent with the goal of reasonably controlling the cost and time that the Parties must expend for discovery; provided that the Arbitrators shall permit such discovery as they deem necessary to permit an
equitable resolution of the Dispute. The arbitration shall be administered by the American Arbitration Association (“AAA”) (or its successor entity) in accordance with the then current Commercial Rules of the American Arbitration
Association including the Procedures for Large, Complex Commercial Disputes (including the Optional Rules for Emergency Measures of Protection), except as modified in this Agreement. The arbitration shall be held in New York, New York, USA, and the
Parties shall use reasonable efforts to expedite the arbitration if requested by either Party. The Arbitrators shall, within 15 days after the conclusion of the arbitration hearing, issue a written award and statement of decision describing the
essential findings and conclusions on which the award is based, including the calculation of any damages awarded. The decision or award rendered by the Arbitrators shall be final and non-appealable, and judgment may be entered upon it in accordance
with applicable Law in the State of New York or any other court of competent jurisdiction. The Arbitrators shall be authorized to award compensatory damages, but shall not be authorized to reform, modify or materially change this Agreement or any
other agreements contemplated hereunder. 
 13.2.3 Each Party shall bear its own counsel fees, costs, and disbursements arising
out of the dispute resolution procedures described in this Section 13.2, and shall pay an equal share of the fees and costs of the Arbitrators and all other general fees related to any arbitration described in Section 13.2.3; provided,
however, the Arbitrators shall be authorized to determine whether a Party is the prevailing Party, and if so, to award to that 

  
 - 31 -

 
prevailing Party reimbursement for its reasonable counsel fees, costs and disbursements (including expert witness fees and expenses, photocopy charges, or travel expenses) or the fees and costs
of the Arbitrators. Unless the Parties otherwise agree in writing, during the period of time that any arbitration proceeding described in Section 13.2.3 is pending under this Agreement, the Parties shall continue to comply with all terms and
provisions of this Agreement. All arbitration proceedings and decisions of the Arbitrator under this 13.2 shall be deemed Confidential Information of both Parties under Section 5 of the Asset Purchase Agreement. For clarity, nothing contained
in this Agreement shall deny either Party the right to seek injunctive or other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed and
maintained notwithstanding any ongoing arbitration proceeding. 
 13.3 Notices. 

13.3.1 Notice Requirements. Any notice, request, demand, waiver, consent, approval or other communication permitted or required
under this Agreement (each, a “Notice”) shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or sent by facsimile transmission (with transmission confirmed) or by
internationally recognized overnight delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified in Section 13.3.2 or to such other address as the Party to whom notice is to be given may
have provided to the other Party at least 10 days’ prior to such address taking effect in accordance with this Section 13.3. Such Notice shall be deemed to have been given as of the date delivered by hand or internationally recognized
overnight delivery service or confirmed that it was received by facsimile (with receipt confirmed by telephone or email). Any Notice delivered by facsimile shall be confirmed by a hard copy delivered as soon as practicable thereafter. 

13.3.2 Address for Notice. 
 If to AstraZeneca, to: 
 AstraZeneca AB 

Pepparredsleden 1 
 S-431 83 Mölndal 
 Attention: President 

Facsimile: +46 31 7763871 
 with a copy (which shall not constitute notice) to: 
 AstraZeneca AB 

Pepparredsleden 1 
 S-431 83 Mölndal 
 Attention: Senior Counsel and Lead, Legal Dept.

 Facsimile: +46 31 7763871 

  
 - 32 -

 and to: 
 Covington & Burling LLP 
 1201 Pennsylvania Avenue, N.W. 

Washington, DC 20004 
 Facsimile: (202) 662-6291 
 Attention: John Hurvitz 

Michael J. Riella 
 If to Horizon, to: 
 Horizon Pharma USA, Inc. 

520 Lake Cook Road, Suite 520 
 Deerfield, Illinois 60015 
 USA 

Facsimile: 847-572-1372 
 Attention: Chief Executive Officer 
 with a copy (which shall not constitute
notice) to: 
 Cooley LLP 
 4401 Eastgate Mall 
 San Diego, California 92121 

USA 

Facsimile: 858-550-6420 
 Attention: L. Kay Chandler, Esq. 
 13.4 No Benefit to Third Parties.
The covenants and agreements set forth in this Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and, except for the rights of Horizon Indemnitees and AstraZeneca Indemnitees under Article 11, they shall
not be construed as conferring any rights on any other Persons. 
 13.5 Waiver and Non-Exclusion of Remedies. Any
term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving
such term or condition. The waiver by any Party of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other Party
whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by applicable Law or otherwise available except as expressly set forth herein. 

13.6 Expenses. Except as otherwise specified herein or in the Asset Purchase Agreement or in any other Ancillary Agreement, each
Party shall bear any costs and expenses incurred by it with respect to the transactions contemplated herein. 

  
 - 33 -

 13.7 Assignment. Except as expressly set forth in this Agreement, neither
Party shall have the right or the power to assign, in whole or in part, any of its rights, or delegate the performance of any of its obligations, under this Agreement without the prior written authorization of the other Party, which authorization
shall not be unreasonably withheld, conditioned or delayed, and any assignment or delegation of this Agreement or any of such rights or obligations without such authorization shall be void and of no effect; provided, however, that either
Party may assign the Agreement, in whole or in part, to an Affiliate without the prior written authorization of the other Party; and provided, further, that either Party shall have the right to assign this Agreement, in whole or in part, in
connection with a merger or other acquisition of the capital stock or all or substantially all of the assets of such assigning Party, without the prior written authorization of the other Party, subject to providing the other Party with written
notice thereof within 30 days after such assignment or delegation. Any permitted assignment or delegation hereunder by a Party shall not relieve such Party of any of its obligations under this Agreement (whether by operation of law or otherwise),
unless, with respect an assignment to a Third Party, such assignee agrees in writing to assume such Party’s obligations under this Agreement, in which case such Party shall be relieved of its obligations hereunder from and after the effective
date of such assignment and assumption. Subject to the foregoing, this Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the Parties and their respective successors and permitted assigns. 

13.8 Use of Affiliates, Third Party Subcontractors. Either Party shall have the right to exercise its rights and perform its
obligations under this Agreement either itself or through any of its Affiliates, or to subcontract any of its rights or obligations under this Agreement to any Third Party, without authorization of the other Party. For clarity this shall not limit
the provisions of Section 2.2 with respect to Sublicensees. 
 13.9 Amendment. This Agreement may not be
modified, amended, altered or supplemented except upon the execution and delivery of a written agreement executed by both Parties. 
 13.10 Independent Contractors. In the exercise of their respective rights, and the performance of their respective obligations, under this Agreement, the Parties are, and shall remain,
independent contractors. Nothing in this Agreement shall be construed to constitute the Parties as partners, joint venturers, or participants in a joint enterprise or undertaking, or to constitute either of the Parties as the agent of the other
Party for any purpose whatsoever. Neither Party shall bind, or attempt to bind, the other Party hereto to any contract or the performance of any other obligation, or represent to any Third Party that it is authorized to enter into any contract or
binding obligation on behalf of the other Party hereto. 
 13.11 Severability. If any provision of this Agreement
is held to be illegal, invalid or unenforceable under any present or future Law, and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a) such provision shall be fully
severable, (b) this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement shall remain in full force and effect
and shall not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom and (d) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this

  
 - 34 -

 
Agreement a legal, valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties. 

13.12 Equitable Relief. The Parties agree that irreparable damage would occur in the event that any of the provisions of
this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce
specifically the terms and provisions of this Agreement in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity. Each Party hereby waives
(a) any requirement that the other Party post a bond or other security as a condition for obtaining any such relief, and (b) any defenses in any action for specific performance, including the defense that a remedy at law would be adequate.

 13.13 English Language. This Agreement shall be written and executed in, and all other communications under or
in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof, and in the event of any conflict in interpretation between the English version and such
translation, the English version shall control. 
 13.14 Counterparts. This Agreement may be executed in any number
of counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement. Delivery of an executed counterpart of a signature page of this Agreement by
facsimile or other electronic transmission shall be effective as delivery of a manually executed original counterpart of this Agreement. 
 13.15 Entire Agreement. This Agreement, together with the Schedules and Exhibits expressly contemplated hereby and attached hereto, the Asset Purchase Agreement and the other Ancillary
Agreements, contain the entire agreement between the Parties with respect to the transactions contemplated hereby and supersede all prior agreements, understandings, promises and representations, whether written or oral, between the Parties with
respect to the subject matter hereof. In the event of any inconsistency between any such Schedules and Exhibits and this Agreement, the terms of this Agreement shall govern. 
 13.16 Construction. Except where the context otherwise requires, wherever used, the singular includes the plural, the plural the singular, the use of any gender shall be applicable to all
genders and the word “or” is used in the inclusive sense (and/or). The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of
any provision contained in this Agreement. The term “including” as used herein does not limit the generality of any description preceding such term. The language of this Agreement shall be deemed to be the language mutually chosen by the
Parties and no rule of strict construction shall be applied against either Party. Unless otherwise specified or where the context otherwise requires, (a) references in this Agreement to any Article, Section, Schedule or Exhibit are references
to such Article, Section, Schedule or Exhibit of this Agreement; (b) references in any Section to any clause are references to such clause of such Section; (c) “hereof,” “hereto,” “hereby,” “herein”
and “hereunder” and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement; (d) references to a Person are also to its permitted

  
 - 35 -

 
successors and assigns; (e) references to a Law include any amendment or modification to such Law and any rules or regulations issued thereunder, in each case, as in effect at the relevant
time of reference thereto; (f) references to any agreement, instrument or other document in this Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently amended, replaced or supplemented from
time to time, as so amended, replaced or supplemented and in effect at the relevant time of reference thereto; and (g) references to monetary amounts are denominated in United States Dollars. 

[Signature page follows] 

  
 - 36 -

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.

  

									
	ASTRAZENECA AB	  		  	HORIZON PHARMA USA, INC.
					
	By:	  	 /s/ Jan-Olof Jacke
	  		  	By:	  	 /s/ Timothy P. Walbert

	Name:	  	Jan-Olof Jacke	  		  	Name:	  	Timothy P. Walbert
	Title:	  	President	  		  	Title:	  	President and Chief Executive Officer

 [SIGNATURE PAGE TO LICENSE
AGREEMENT] 

 Schedule 1.29 

Licensed Trademarks 
  

											
	 Country
	 	 Mark
	 	 App Date /

Reg Date
	 	 App No /

Reg No
	 	 Goods
	 	 Status

	 United States
	 	 VIMOVO & Design
 

	 	 App 01-MAY-2009

Reg 01-FEB-2011
	 	 App 77726998

Reg 3914867
	 	(Class 5) pharmaceutical preparations and substances for the treatment of pain and inflammation	 	REGISTERED
						
	 United States
	 	VIMOVO	 	 App 13-FEB-2009

Reg 05-APR-2011
	 	 App 77670350
 Reg
3941225
	 	(Class 5) pharmaceutical preparations and substances for the treatment of pain and inflammation	 	REGISTEREDEX-10.45

 Exhibit 10.45 

***Text Omitted and Filed Separately with the Securities and Exchange Commission. 

Confidential Treatment Requested Under 

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 

Execution Version 

SUPPLY AGREEMENT 

THIS SUPPLY AGREEMENT (“Agreement”) is made and
entered into effective as of November 22, 2013 (the “Effective Date”), by and between ASTRAZENECA LP, a Delaware limited partnership
(“AstraZeneca”), having offices at 1800 Concord Pike, Wilmington, Delaware 19803, and Horizon Pharma USA, Inc., a Delaware corporation (“Horizon”), having an office at 520 Lake Cook Road, Suite 520,
Deerfield, Illinois 60015. AstraZeneca and Horizon each may be referred to herein individually as a “Party,” or collectively as the “Parties.” 

RECITALS 

A. AstraZeneca controls certain patents and other intellectual property pertaining to pharmaceutical products having gastroprotective agents
in single fixed combination oral solid dosage form with non-steroidal anti-inflammatory drugs. 
 B. Horizon and AstraZeneca AB, an
Affiliate of AstraZeneca, are parties to that certain (i) Asset Purchase Agreement dated as of November 18, 2013 (as may be amended, the “Asset Purchase Agreement”) under which, among other things, effective as of
the Closing (as defined in the Asset Purchase Agreement), Horizon is purchasing from AstraZeneca AB certain assets relating to Products (as defined in the Asset Purchase Agreement) in the Field (as defined in the Asset Purchase Agreement) in the
Horizon Territory (as defined in the Asset Purchase Agreement) and (ii) License Agreement of even date herewith (as may be amended, the “License Agreement”), under which, among other things, effective as of the Closing
(as defined in the Asset Purchase Agreement), Horizon is obtaining an exclusive license to certain of AstraZeneca AB’s intellectual property for the purpose of manufacturing, developing and commercializing Products in the Field in the Horizon
Territory. 
 C. AstraZeneca desires to supply to Horizon, and Horizon desires to obtain from AstraZeneca, on a transitional basis the
Supplied Products (as defined herein) on the terms and conditions set forth herein. 
 In consideration of the foregoing premises, the
mutual promises and covenants set forth in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, AstraZeneca and Horizon hereby agree as follows: 

AGREEMENT 
 1.
Definitions 
 When used in this Agreement, capitalized terms have the meanings as defined below and throughout this Agreement and
capitalized terms used but not otherwise defined herein have the respective meanings ascribed thereto in the Asset Purchase Agreement. 

1.1 “AAA” has the meaning assigned to it in Section 14.3.2. 

1.2 “Agreement” has the meaning assigned to it in the preamble hereto. 

 1.3 “API” means micronized Esomeprazole magnesium trihydrate and Naproxen as
further described in the applicable Product Specifications. 
 1.4 “Arbitration Notice” has the meaning assigned to
it in Section 14.3.2. 
 1.5 “Arbitrators” has the meaning assigned to it in Section 14.3.2. 

1.6 “Asset Purchase Agreement” has the meaning assigned to in the recitals. 

1.7 “AstraZeneca” has the meaning assigned to it in the preamble hereto. 

1.8 “AstraZeneca Indemnitee” has the meaning assigned to it in Section 12.2 (Indemnification by Horizon). 

1.9 “Bailment Agreement” means that certain Bailment Agreement executed and delivered by the Parties on the Effective
Date. 
 1.10 “Bailment Product” means any Supplied Product delivered to Horizon prior to the Bailment Product
Transfer Date. 
 1.11 “Bailment Product Transfer Date” has the meaning set forth in the Bailment Agreement. 

1.12 “Breaching Party” has the meaning as defined in Section 11.2 (Termination for Material Breach). 

1.13 “Calendar Quarter” means the respective periods of three (3) consecutive calendar months ending on
March 31, June 30, September 30 and December 31. 
 1.14 “Dispute” has the meaning assigned to it
in Section 14.3.1. 
 1.15 “Commercialization” means all activities relating to the marketing, promotion,
advertising, selling and distribution of Supplied Product in the Horizon Territory, including preparing advertising and promotional materials, sales force training and all interactions and activities regarding the commercialization of Supplied
Product and the maintenance of Regulatory Approvals. 
 1.16 “Effective Date” has the meaning assigned to it in the
preamble hereto. 
 1.17 “EMA” means the European Medicines Agency, or any successor agency thereto. 

1.18 “Existing Regulatory Approval” means NDA# 22-511. 

1.19 “Existing Product” means that certain product containing non-enteric coated Esomeprazole and enteric-coated
Naproxen that is the subject of the Existing Regulatory Approval in the Horizon Territory, which product is currently known as VIMOVOTM including all dosage strengths thereof. 

1.20 “Firm Forecast” has the meaning assigned to it in Section 3.1.3. 

  
 2. 

 1.21 “Forecast” has the meaning assigned to it in Section 3.1.2.

 1.22 “Force Majeure Event” has the meaning assigned to it in Section 14.5. 

1.23 “Horizon” has the meaning assigned to it in the preamble hereto. 

1.24 “Horizon Indemnitee” has the meaning assigned to it in Section 12.1 (Indemnification by AstraZeneca). 

1.25 “Horizon Intellectual Property” means (a) any data, information and know-how that (i) is not generally
known, (ii) is Controlled by Horizon or its Affiliates as of the Effective Date or during the Term and (iii) is necessary or useful for AstraZeneca to Manufacture the Supplied Products hereunder; (b) any Patent Right that (i) is
Controlled by Horizon or its Affiliates as of the Effective Date or during the Term and (ii) is necessary or useful for AstraZeneca to Manufacture the Supplied Products hereunder; (c) any Horizon Marks; and (d) any Licensed Trademark.

 1.26 “Horizon Marks” means the trade names, corporate names and corporate logos of Horizon or Horizon’s
Affiliates that are used by Horizon or any of Horizon’s Affiliates in connection with the Supplied Product. 
 1.27
“Horizon Regulatory Documentation” has the meaning assigned to it in the License Agreement. 
 1.28
“Initial Forecast” has the meaning assigned to it in Section 3.1.1. 
 1.29 “Initial Purchase
Orders” has the meaning assigned to it in Section 3.2.1. 
 1.30 “Indirect Taxes” has the meaning assigned
to it in Section 4.3.2 (Indirect Taxes). 
 1.31 “License Agreement” has the meaning assigned to it in the
preamble hereto. 
 1.32 “Licensed Trademarks” has the meaning assigned to it in the License Agreement. 

1.33 “Manufacturing Process” has the meaning assigned to it in Section 7.3 (Manufacturing Process). 

1.34 “Manufacture” and “Manufacturing” means all activities related to the production, manufacture,
processing, filling, finishing, packaging, labeling, shipping and holding of the Supplied Product or any intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial
manufacture and analytic development, product characterization, stability testing, quality assurance and quality control. 
 1.35
“Manufacturing Technology” means (a) as of the Effective Date, all Patent Rights and all data, information and know-how that (i) with respect to data, information and know-how, is not generally known, (ii) are
Controlled by AstraZeneca or any of its Affiliates as 

  
 3. 

 
of the Effective Date and (iii) are used by or on behalf of AstraZeneca or its Affiliates for the Manufacture of Supplied Products as of the Effective Date and (b) as of the date, if
any, that AstraZeneca or any of its Affiliates may grant a license to Horizon under the Merck Patents and Merck Know-How without violating the terms of any Merck Agreement, the Patent Rights, data, information and know-how described in clause
(a) and any Merck Patents and Merck Know-How that are used by or on behalf of AstraZeneca or its Affiliates for the Manufacture of Supplied Products as of the Effective Date; provided, that in either case ((a) or (b)), if any data,
information or know-how (but not, for clarity, Patent Rights) included in Manufacturing Technology becomes publicly disclosed (other than as a result of any disclosure by Horizon in breach of its obligations under Section 5.5 of the Asset
Purchase Agreement), such data, information or know-how shall no longer be deemed Manufacturing Technology. 
 1.36 “Minimum
Batch Quantity” means (a) with respect to the Supplied Product in the form of 500/20mg tablets in 60-count bottles, [...***...] bottles; (b) with respect to the Supplied Product in the form of 375/20mg tablets in 60-count
bottles, [...***...] bottles; and (c) with respect to the Supplied Product in the form of 500/20mg tablets in 6-count bottles, [...***...] bottles. 

1.37 “Non-Breaching Party” has the meaning assigned to it in Section 11.2 (Termination for Material Breach). 

1.38 “Notice” has the meaning assigned to it in Section 14.4 (Notice Requirements). 

1.39 “Notice Period” has the meaning assigned to it in Section 11.2 (Termination for Material Breach). 

1.40 “Package” and “Packaging” mean the acts of packaging and labeling the Existing Product in bulk
form into Supplied Product. 
 1.41 “Packaging Technology” means all Manufacturing Technology that is necessary or
useful for the packaging and labeling of the Existing Product in bulk form into Supplied Product and set forth on Schedule 1.41. 
 1.42
“Party” and “Parties” each has the meaning assigned to it in the preamble hereto. 
 1.43
“Pass-Through Affiliate” means, with respect to a Pass-Through Supply Agreement, any Affiliate of AstraZeneca that is party to such Pass-Through Supply Agreement. 

1.44 “Pass-Through Supply Agreements” means those agreements set forth on Schedule 1.44. 

1.45 “Pass-Through Supply Vendor” means the party to a Pass-Through Supply Agreement other than AstraZeneca or a
Pass-Through Affiliate. 
 1.46 “Patheon Agreement” means that certain Manufacturing Services Agreement by and
between Patheon, Inc., Patheon Pharmaceuticals, Inc. and AstraZeneca LP, dated February 24, 2010. 
 1.47
“Payments” has the meaning assigned to it in Section 4.3.1 (Payments). 

  
  

	***	Confidential Treatment Requested 

 4. 

 1.48 “Product Labeling” means (a) the full prescribing information
for a Supplied Product approved by the applicable Regulatory Authority in the Horizon Territory, and (b) all labels and other written, printed or graphic information included in or placed upon any container, wrapper or package insert used with
or for a Supplied Product in the Horizon Territory. 
 1.49 “Product Specifications” means the specifications for the
Supplied Product contained in the applicable Regulatory Approval and any specifications mutually agreed to by the Parties established in connection with the Supplied Product and changes to such specifications made at the request of a Regulatory
Authority in the Horizon Territory or by mutual agreement of the Parties from time to time, including the specifications set forth on Schedule 1.49. 

1.50 “Purchase Order” has the meaning assigned to it in Section 3.2.3. 

1.51 “Quality Agreement” has the meaning assigned to it in Section 6.1 (Quality Agreement). 

1.52 “Raw Materials” has the meaning assigned to it in Section 7.1 (Raw Materials). 

1.53 “Recall” has the meaning set forth in the Quality Agreement. 

1.54 “SKU” means, with respect to any Supplied Product, the stock keeping unit number identifying the individual
presentation of such Supplied Product. 
 1.55 “Sublicensee” means a Third Party that is granted a sublicense by
Horizon under the grant in Section 2.1 of the License Agreement, in accordance with Section 2.2 of the License Agreement. 

1.56 “Subsequent Purchase Order” has the meaning assigned to it in Section 3.2.3. 

1.57 “Supplied Product” means the Existing Product in analyzed, released, final, packaged and labeled form, including
all Product Labeling, ready for Commercialization in the Field in the Horizon Territory, as further described in the Product Specifications. The Supplied Product does not include HUD blister packs. 

1.58 “Technology Recipient” has the meaning assigned to it in Section 2.3.1 (Technology Transfer). 

1.59 “Technology Transfer Notice” has the meaning assigned to it in Section 2.3.1 (Technology Transfer). 

1.60 “Term” has the meaning assigned to it in Section 11.1 (Term). 

1.61 “Third Party” means any entity other than AstraZeneca, Horizon, or any of their respective Affiliates. 

1.62 “Third Party Claim” has the meaning assigned to it in Section 12.1 (Indemnification of AstraZeneca). 

  
 5. 

 1.63 “Transfer Price” has the meaning assigned to it in Section 4.1
(Transfer Price). 
 2. SUPPLY OF SUPPLIED PRODUCTS. 

2.1 Supply by AstraZeneca. During the Term, subject to the terms and conditions of this Agreement, AstraZeneca will Manufacture or have
Manufactured and supply or have supplied to Horizon such quantities of Supplied Products, including samples, as requested by Horizon for use by Horizon and its Sublicensees in connection with activities with respect to Supplied Products in the
Horizon Territory, including Exploitation activities in the Horizon Territory. 
 2.2 Supply Transition. AstraZeneca or its applicable
Pass-Through Affiliate will coordinate with each Pass-Through Supply Vendor to enable such Pass-Through Supply Vendor to supply the Supplied Products, or any component thereof, for the benefit of Horizon solely for use in the Horizon Territory
without breaching any of the terms of the applicable Pass-Through Supply Agreement (including by entering into any necessary side letters or amending the applicable Pass-Through Supply Agreement, in each case in accordance with Section 14.1
(AstraZeneca’s Third Party Manufacturers)). Without limiting the foregoing, promptly after the Effective Date, AstraZeneca will cause AstraZeneca AB to deliver a side letter in substantially the form of Exhibit A to Patheon Inc. and Patheon
Pharmaceuticals Inc. 
 2.3 Technology Transfer. 

2.3.1 Horizon shall have the right, at any time during the Term, to provide notice to AstraZeneca requesting transfer to Horizon or its
designated Third Party manufacturer (the “Technology Recipient”) of all Packaging Technology (the “Technology Transfer Notice”). Promptly following the date of such Technology Transfer Notice, the
Parties shall work together to agree to a plan for transitioning the Packaging Technology to the Technology Recipient, and each Party shall use commercially reasonable efforts to perform its obligations under such plan in accordance with the
timelines set out therein. Such plan shall provide for the transfer by AstraZeneca to the Technology Recipient, at Horizon’s expense, all Packaging Technology; provided, however, that AstraZeneca shall provide up to [...***...] of
technology transfer services at no cost to Horizon in connection with the transfer of the Packaging Technology to Horizon or the Technology Recipient (and in providing reasonable assistance in connection therewith). In the event that Horizon desires
additional technology transfer services with respect to the transfer of the Packaging Technology beyond the [...***...] of assistance provided above, at Horizon’s reasonable request and upon the payment of [...***...] to AstraZeneca,
AstraZeneca shall provide up to [...***...] of additional technology transfer services, provided that AstraZeneca’s other Manufacturing operations are not disrupted by the provision of such additional assistance. 

2.3.2 In no event shall AstraZeneca be required to transfer the Packaging Technology to more than one Technology Recipient. Horizon (or
the Technology Recipient at Horizon’s direction) shall obtain and make available such information, personnel, products, materials, services, facilities and other resources, and take such other actions, as are reasonably necessary or useful to
enable AstraZeneca to transfer the Packaging Technology to the Technology Recipient, including those set forth in the technology transfer plan to be agreed to by 

  
  

	***	Confidential Treatment Requested 

 6. 

 
the Parties. Horizon acknowledges that the timely and successful transfer of the Packaging Technology to the Technology Recipient depends on the provision of information, personnel, products,
materials, services, facilities and other resources by or on behalf of Horizon or the taking of certain actions by or on behalf of Horizon. Horizon acknowledges and agrees that AstraZeneca provides no assurances or guarantee that the Packaging
Technology may be successfully transferred to the Technology Recipient. 
 2.3.3 Limited License. Horizon, on behalf of itself and its
Affiliates, hereby grants to AstraZeneca and its Affiliates a non-exclusive, royalty-free, fully paid-up non-transferable (except as provided in Section 14.8) license under the Horizon Intellectual Property and a right of reference and use
under the Horizon Regulatory Documentation, with the right, to grant further licenses and sublicenses or rights of reference and use, in each case, to the extent necessary for AstraZeneca and its Affiliates to perform their obligations hereunder.

 3. FORECASTS AND PURCHASE ORDERS. 

3.1 Forecasts. 
 3.1.1
Horizon’s written rolling, non-binding (except as set forth in Section 3.1.3) forecast of its and its Sublicensees’ anticipated requirements for Supplied Product in the Horizon Territory broken out on a month-by-month basis by SKU
(in multiples of Minimum Batch Quantities) for the twelve-month period beginning January 1, 2014 (the “Initial Forecast”) is attached as Schedule 3.1.1. 

3.1.2 Beginning on December 5, 2013, Horizon shall provide AstraZeneca, on or before the [...***...] day of each calendar month
during the Term, with a written rolling, non-binding (except as set forth in Section 3.1.3) forecast of its and its Sublicensees’ anticipated requirements for Supplied Product in the Horizon Territory broken out on a month-by-month basis
by SKU (in multiples of Minimum Batch Quantities), for the shorter of the twelve (12)-month period beginning with such calendar month and the remainder of the Term (each, a “Forecast”, and together with the Initial Forecast,
the “Forecasts”). 
 3.1.3 The first (1st) [...***...] months of each Forecast shall be binding on
Horizon (each, a “Firm Forecast”) and may not be changed without AstraZeneca’s written consent (which may be withheld in its sole discretion). The forecasted quantity of each Supplied Product SKU for each of the
[...***...] months of a given Forecast shall not be more than [...***...] or less than [...***...] of the forecasted quantity for such Supplied Product SKU for such month in the immediately preceding Forecast. 

3.2 Purchase Orders.  

3.2.1 Horizon shall order Supplied Product by submitting written purchase orders to AstraZeneca pursuant to the terms of this
Section 3.2. 
 3.2.2 Horizon’s binding written purchase orders to AstraZeneca specifying the quantities of each Supplied
Product SKU ordered by Horizon for delivery during December 2013 and each month during the first Calendar Quarter of 2014 (the “Initial Purchase Orders”) are 

  
  

	***	Confidential Treatment Requested 

 7. 

 
attached as Schedule 3.2.2. 
 3.2.3 Subject to Section 3.2.2, at least
[...***...] prior to the first (1st) day of each calendar month during the Term, Horizon shall submit to AstraZeneca a binding written purchase order to AstraZeneca, in a form
reasonably acceptable to AstraZeneca, specifying the quantities of each Supplied Product SKU to be delivered to Horizon and its Sublicensees during such month, which quantities shall be the Minimum Batch Quantity for the applicable Supplied Product
SKU, or a multiple thereof (each, a “Subsequent Purchase Order”, and together with the Initial Purchase Orders, the “Purchase Orders”). 

3.2.4 AstraZeneca shall make each delivery of Supplied Product in the quantity and during the applicable month specified for it on
Horizon’s Purchase Order[...***...]. In the event that the quantity of Supplied Product delivered by AstraZeneca differs from the quantity requested in the applicable Purchase Order, Horizon shall pay AstraZeneca for the quantity of Supplied
Products delivered, rather than the quantity ordered, to the extent that the quantity delivered is not more than [...***...] of the quantity required in the Purchase Order. The quantity of each Supplied Product SKU specified in any Purchase Order
submitted by Horizon to AstraZeneca for delivery in the applicable month shall be the quantity of such Supplied Product SKU forecasted by Horizon in the Firm Forecast for such month. Any Purchase Order for Supplied Product submitted by Horizon to
AstraZeneca shall reference this Agreement and shall be governed exclusively by the terms contained herein. The Parties hereby agree that the terms and conditions of this Agreement shall supersede any term or condition in any order, confirmation or
other document furnished by Horizon or AstraZeneca that is in any way inconsistent with these terms and conditions. 
 4. TRANSFER
PRICE AND TAXATION. 
 4.1 Transfer Price. Horizon will pay AstraZeneca the transfer
price set forth on Schedule 4.1 (the “Transfer Price”) for Supplied Products supplied by AstraZeneca to Horizon and its Sublicensees under this Agreement. 

4.2 Invoices; Method of Payments. 

4.2.1 AstraZeneca shall invoice Horizon for the aggregate Transfer Price of: (a) each delivery of Supplied Products that are not
Bailment Products, at the time of such delivery and (b) each delivery of Bailment Products, any time after the Bailment Product Transfer Date. 

4.2.2 All payments due hereunder to AstraZeneca shall be paid to AstraZeneca in U.S. Dollars not later than [...***...] days following
the date of the applicable invoice but not earlier than the date of delivery, unless such delivery of Supplied Product is rejected in accordance with the provisions of Section 6.2.1 (Rejection of Non-Conforming Supplied Products). All amounts
due hereunder will be paid in United States Dollars by check sent to such address as may be designated in writing by AstraZeneca from time to time during the Term. 

4.2.3 If AstraZeneca does not receive payment of any sum due to it on or before 

  
  

	***	Confidential Treatment Requested 

 8. 

 
the due date, simple interest will thereafter accrue on the sum due beginning on the [...***...] Business Day after the due date until
the date of payment at the per annum rate of the then-current [...***...] quoted by Citibank in New York City plus [...***...] basis points, or the maximum rate allowable by applicable Law, whichever is lower. 

4.3 Taxes. 

4.3.1 The amounts payable by Horizon to AstraZeneca pursuant to this Agreement (“Payments”) shall not be reduced on
account of any Taxes unless required by applicable Law. AstraZeneca alone shall be responsible for paying any and all Taxes (other than withholding Taxes required to be paid by Horizon levied on account of, or measured in whole or in part by
reference to, any Payments it receives. Horizon shall deduct or withhold from the Payments any Taxes that it is required by applicable Law to deduct or withhold. Notwithstanding the foregoing, if AstraZeneca is entitled under any applicable Tax
treaty to a reduction of rate of, or the elimination of, or recovery of, applicable withholding tax, it may deliver to Horizon or the appropriate Governmental Authority (with the assistance of Horizon to the extent that this is reasonably required
and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Horizon of its obligation to withhold Tax, and Horizon shall apply the reduced rate of withholding, or dispense with the
withholding, as the case may be, provided that Horizon has received evidence, in a form reasonably satisfactory to Horizon, of AstraZeneca’s delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental
authorization) at least fifteen (15) days prior to the time that the Payments are due. If, in accordance with the foregoing, Horizon withholds any amount, it shall pay to AstraZeneca the balance when due, make timely payment to the proper
taxing authority of the withheld amount, and send to AstraZeneca proof of such payment within sixty (60) days following that payment. 

4.3.2 “Indirect Taxes” means value added taxes, sales taxes, consumption taxes and other similar taxes. All Payments
are exclusive of Indirect Taxes. If any Indirect Taxes are chargeable in respect of any Payments, Horizon shall pay such Indirect Taxes at the applicable rate in respect of any such Payments following the receipt, where applicable, of an Indirect
Taxes invoice in the appropriate form issued by AstraZeneca in respect of those Payments. AstraZeneca shall issue invoices for all amounts payable under this Agreement consistent with Indirect Tax requirements and irrespective of whether the sums
may be netted for settlement purposes. 
 5. DELIVERY. AstraZeneca will deliver Supplied Products to Horizon in such quantities and
during the applicable month as are specified in Purchase Orders subject to the terms and conditions of this Agreement. Deliveries shall be made [...***...] (Incoterms 2012) [...***...]. For clarity, [...***...] shall be responsible for the freight
and insurance costs of delivery of the Supplied Products [...***...]. Except with respect to the Bailment Product, title and risk of loss for the Supplied Products shall [...***...] in accordance with this Section 5. Title and risk of loss with
respect to the Bailment Product shall be governed by the Bailment Agreement. 

  
  

	***	Confidential Treatment Requested 

 9. 

 6. QUALITY ASSURANCE; ACCEPTANCE. 

6.1 Quality Agreement. Concurrently with execution of this Agreement, the Parties will enter into an agreement that details the quality
assurance obligations of each Party with respect to the Manufacture and supply of Supplied Products under this Agreement (the “Quality Agreement”). Each Party shall perform its obligations under the Quality Agreement in
accordance with the terms and conditions thereof. In the event of a conflict between the terms of the Quality Agreement and the terms of this Agreement, the provisions of the Quality Agreement shall govern. 

6.2 Acceptance and Rejection. 

6.2.1 Rejection of Non-Conforming Supplied Products. Horizon may reject any delivery (or portion thereof) of Supplied Product pursuant
to the terms of the Quality Agreement. 
 6.2.2 Cost of Replacement of Rejected Product. If any delivery of Supplied Product is
rejected by Horizon pursuant to the provisions of the Quality Agreement, [...***...]. If only a portion of a delivery is rejected, [...***...]. 

6.2.3 Return of Rejected Product. If a delivery or partial delivery is rejected by Horizon pursuant to the provisions of the Quality
Agreement and there is a determination pursuant to Section 9.1 of the Quality Agreement that such Supplied Product fails to conform to any warranty set forth in Section 9.1 (Supplied Product Warranty), Horizon shall return to AstraZeneca
at AstraZeneca’s request and expense (or, at the election of AstraZeneca, destroy at AstraZeneca’s cost and provide evidence of such destruction to AstraZeneca) any such rejected Supplied Product. AstraZeneca shall (a) credit the
original invoice in respect of the rejected Supplied Product, and (b) adjust the invoice to Horizon for any Supplied Product that was not rejected, payment of which is due in accordance with the terms of the original invoice. Except as set
forth in Section 12.1 (Indemnification by AstraZeneca), this Section 6.2.3 (Return of Rejected Product) shall be Horizon’s sole remedy if AstraZeneca supplies Horizon Supplied Product that fails to conform to any warranty set forth in
Section 9.1 (Supplied Product Warranty). 
 6.2.4 Supply of Replacement Product. During the pendency of any rejection discussions
AstraZeneca shall use commercially reasonable efforts to supply Horizon with additional Supplied Product, which Horizon shall purchase on the same terms as the Supplied Product that is the subject of the rejection discussions. 

7. MANUFACTURE OF SUPPLIED PRODUCT. 

7.1 Raw Materials. AstraZeneca shall be responsible for obtaining and storing, at no cost to Horizon (subject to Section 4.1
(Transfer Price)), all materials required for the Manufacture of Supplied Products including all API, raw materials, components and other 

  
  

	***	Confidential Treatment Requested 

 10. 

 
ingredients, and all Product Labeling and containers, wrappers and other packaging materials (collectively, “Raw Materials”) required for the Manufacture of the Supplied
Products hereunder. AstraZeneca shall have the right to change any source of Raw Materials; provided, however, that any change to the source of Raw Materials that would require approval by, or notification to, a Regulatory Authority (other
than the annual report to the FDA for the Existing Product) shall be subject to the prior written approval of Horizon, such approval not to be unreasonably conditioned, withheld or delayed. 

7.2 Manufacture of Supplied Product. AstraZeneca will Manufacture (to the extent AstraZeneca Manufactures), and will use its
commercially reasonable efforts to cause the Pass-Through Supply Vendors to Manufacture, Supplied Products in accordance with the Product Specifications, cGMPs and applicable Law. 

7.3 Costs of Changes to Product Specifications and Manufacturing Process. The procedures governing changes to the Product
Specifications or the process or procedures used to Manufacture the Supplied Product (the “Manufacturing Process”) shall be set forth in the Quality Agreement. If any change to the Product Specifications or Manufacturing
Process is proposed by AstraZeneca, then AstraZeneca shall bear any expenses of implementing such change. For changes to the Product Specifications or Manufacturing Process proposed by Horizon (including any change that is required solely by a
Regulatory Authority in the Horizon Territory), Horizon promptly shall reimburse AstraZeneca for all reasonable internal and external costs incurred by AstraZeneca or any Pass-Through Affiliate (including any and all costs AstraZeneca or any
Pass-Through Affiliate must pay to a Pass-Through Supply Vendor) in connection with the implementation of any such change. 
 7.4 Shelf
Life. Supplied Products will have a remaining shelf life of at least [...***...] months from the date of delivery, unless otherwise agreed by the Parties in writing, such agreement not to be unreasonably conditioned, withheld or delayed. 

7.5 Supplied Product Shortfall. AstraZeneca shall use commercially reasonable efforts to avoid shortfalls in supply of Supplied Products
based on the Forecasts provided by Horizon. In the event AstraZeneca is unable to supply to Horizon, in whole or in part, Supplied Products requested for any reason (except to the extent caused by Horizon), then AstraZeneca shall promptly notify
Horizon, in writing, of such shortage, or potential shortage, or inability to timely supply Supplied Product and, if possible, the date when AstraZeneca will again be able to supply Supplied Product. AstraZeneca will use commercially reasonable
efforts to remedy any shortfall of Supplied Product as soon as practicable and AstraZeneca will allocate its available production capacity at its facility located at [...***...] for the production of Supplied Product in a manner proportional to the
utilization of AstraZeneca and Horizon, respectively, of such capacity in the prior [...***...] period and will allocate such Supplied Product on a proportional basis with respect to remaining shelf-life as well; provided, that in connection
with any such shortfall, AstraZeneca shall not be required to supply Supplied Product from its own inventories or from orders for Supplied Product for the AstraZeneca Territory ordered pursuant to the [...***...] Agreement or to incur any capital or
other expenditures in connection therewith. 

  
  

	***	Confidential Treatment Requested 

 11. 

 8. REGULATORY. 

8.1 Regulatory Compliance. AstraZeneca shall comply with all regulatory requirements with respect to Manufacture and supply of Supplied
Product imposed by applicable Law upon AstraZeneca as the Manufacturer of the Supplied Product. 
 8.2 Recall of Supplied Product. The
procedures governing Recall of Supplied Product shall be set forth in the Quality Agreement. In the event that any Supplied Product is Recalled in the Horizon Territory, Horizon shall be responsible for all costs and expenses related to such Recall
and shall reimburse AstraZeneca or its applicable Pass-Through Affiliate for any out-of-pocket expenses incurred in connection with any such Recall, including any amounts payable to any Pass-Through Supply Vendors with respect thereto.
Notwithstanding the foregoing, to the extent a Recall results from the nonconformance of Supplied Product supplied by AstraZeneca hereunder with each warranty set forth in Section 9.1 (Supplied Product Warranty), AstraZeneca shall reimburse
Horizon for all out-of-pocket expenses incurred by Horizon with respect to such Recall. 
 9. REPRESENTATIONS AND
WARRANTIES. 
 9.1 Supplied Product Warranty. AstraZeneca represents and warrants that, as of the date of delivery,
all Supplied Product delivered hereunder will (a) be Manufactured by AstraZeneca in accordance with all applicable Regulatory Approvals, cGMPs and other applicable Law; (b) conform to the Product Specifications at the time of delivery;
(c) have a remaining shelf life of at least [...***...] months from the date of delivery, unless otherwise agreed by the Parties in writing; (d) at the time of delivery, be free and clear of any pledges, liens, charges, security
interests, leases, title retention agreements, mortgages, restrictions, development or similar agreements, easements, rights-of-way, title defects, options, or adverse claims or encumbrances of any kind or character whatsoever, and (e) be
supplied in accordance with the Quality Agreement[...***...]. 
 9.2 Other AstraZeneca Representations and Warranties. AstraZeneca
represents and warrants to Horizon that (a) Schedule 9.2(a) sets forth all Third Party manufacturers engaged by AstraZeneca and its Affiliates to Manufacture or supply Supplied Products, including API and other Raw Materials used to Manufacture
Supplied Products, (b) neither AstraZeneca nor any Affiliate, in any capacity, in connection with the Manufacture of Supplied Products, has been debarred or is subject to debarment or has otherwise been disqualified or suspended from performing
scientific or clinical investigations or otherwise subjected to any restrictions or sanctions by the FDA or any other governmental or Regulatory Authority or professional body with respect to the performance of scientific or clinical investigations,
and (c) neither AstraZeneca nor any Affiliate, in any capacity, in connection with the Manufacture of the Supplied Product has received in the past [...***...] years or is currently subject to a Warning Letter (as defined in the Act) with
respect to any facility Manufacturing Supplied Product. AstraZeneca shall, or shall cause its Pass-Through Affiliates to, provide Horizon with the benefit of any warranties with respect to the subject matter in clauses (b) and (c) that
AstraZeneca or its 

  
  

	***	Confidential Treatment Requested 

 12. 

 
Pass-Through Affiliates obtained from the Pass-Through Supply Vendors with respect to the Manufacture of Supplied Products (or components thereof) under the Pass-Through Supply Agreements, and
AstraZeneca shall use commercially reasonable efforts to pursue or cause the applicable Pass-Through Affiliate to use commercially reasonable efforts to pursue all remedies available to AstraZeneca or the applicable Pass-Through Affiliate under the
Pass-Through Supply Agreement for any breach of any such warranties. 
 9.3 Reciprocal Representations and Warranties. Each Party
represents and warrants to the other Party that: (a) this Agreement is a legal and valid obligation binding upon its execution and enforceable against it in accordance with its terms and conditions; and (b) the execution, delivery and
performance of this Agreement by such Party has been duly authorized by all necessary corporate action, and the person executing this Agreement on behalf of such Party has been duly authorized to do so by all requisite corporate actions. 

9.4 Disclaimer of Warranties. EXCEPT FOR THE EXPRESS REPRESENTATIONS AND WARRANTIES SET FORTH IN SECTIONS 9.1 (ASTRAZENECA WARRANTIES),
SECTION 9.2 (RECIPROCAL REPRESENTATIONS AND WARRANTIES) OR IN THE ASSET PURCHASE AGREEMENT, EACH PARTY MAKES NO REPRESENTATIONS AND GRANTS NO WARRANTIES WITH RESPECT TO THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, EXPRESS OR IMPLIED, EITHER IN
FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND ASTRAZENECA AND HORIZON EACH SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY OR MERCHANTABILITY, OR ANY WARRANTY
AS TO THE VALIDITY OR ENFORCEABILITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 
 9.5
Other Covenants. 
 9.5.1 Each Party shall comply with all applicable Law in performing its obligations under this
Agreement. 
 9.5.2 AstraZeneca shall not employ, contract with, or retain any person directly or indirectly to perform any services
under this Agreement if such a person (a) is under investigation by the FDA for debarment or is presently debarred by the FDA pursuant to 21 U.S.C. § 335a or its successor provisions, or (b) has a disqualification hearing pending or
has been disqualified by the FDA pursuant to 21 C.F.R. § 312.70 or its successor provisions. If, during the Term, AstraZeneca or any person employed or retained by it to perform under this Agreement (excluding any Pass-Through Supply Vendor)
(i) comes under investigation by the FDA for a debarment action or disqualification, (ii) is debarred or disqualified, or (iii) engages in any conduct or activity that could lead to any of the above-mentioned disqualification or
debarment actions, AstraZeneca shall immediately notify Horizon of same; provided AstraZeneca shall use commercially reasonable efforts to require the same or similar obligations from its Pass-Through Supply Vendors and shall provide Horizon
with the benefit of any warranties with respect to the subject matter. 

  
 13. 

 9.5.3 AstraZeneca has and will maintain (or, as applicable, will use commercially
reasonable efforts to cause the applicable Pass-Through Supply Vendors to maintain) during the Term all government permits, including, health, safety and environmental permits, necessary for the conduct of the activities that it undertakes pursuant
to this Agreement. 
 9.5.4 As between AstraZeneca and Horizon, Horizon shall be responsible for ensuring that the Product
Specifications shall comply with all applicable Regulatory Approvals, cGMPs and other applicable Law. 
 10. CONFIDENTIALITY 

10.1 General. The rights and obligations of the Parties with respect to Confidential Information disclosed by or on behalf of one Party
to the other Party hereunder shall be governed by the terms of Section 9.1 of the License Agreement. 
 11. TERM AND
TERMINATION 
 11.1 Term. The term of this Agreement will commence as of the Effective Date and, unless earlier
terminated in accordance with this Section 11 (Term and Termination), will expire on December 31, 2014 (the “Term”). 

11.2 Termination for Material Breach. In the event that either Party (the “Breaching Party”) is in material
default of any of its material obligations under this Agreement, in addition to any other right and remedy the other Party (the “Non-Breaching Party”) may have, the Non-Breaching Party may terminate this Agreement by [...***...] days’ prior written notice (such [...***...]-day period, the “Notice Period”) to the Breaching Party, specifying the breach and its claim of right to terminate;
provided, that the termination shall not become effective at the end of the Notice Period if the Breaching Party cures the breach complained about during the Notice Period (or, if such default cannot be cured within such Notice Period, if the
Breaching Party commences actions to cure such default within the Notice Period and thereafter diligently continues such actions). [...***...] If either Party initiates a dispute resolution procedure as permitted under Section 14.3 (Dispute
Resolution) to resolve the dispute for which termination is being sought and is diligently pursuing such procedure, including any arbitration following therefrom, the termination shall become effective only if and when such dispute is finally
resolved through such dispute resolution procedure. This Section 11.2 (Termination for Material Breach) defines exclusively the Parties’ right to terminate in case of any material breach of this Agreement. 

11.3 Other Termination by Horizon. Horizon may terminate this Agreement at any time at will upon one hundred twenty (120) days
prior written notice to AstraZeneca. In addition, Horizon may terminate this Agreement immediately upon written notice to AstraZeneca if (a) the Existing Regulatory Approval is suspended for any reason or (b) any Regulatory Authority
provides a Warning Letter (as defined in the Act) or other official documentation expressing major and significant concerns from a regulatory perspective with 

  
  

	***	Confidential Treatment Requested 

 14. 

 
respect to AstraZeneca’s or its Affiliate’s or any Pass-Through Vendors’ Manufacturing of Supplied Products. 

11.4 Termination for Insolvency. This Agreement may be terminated by written notice by either Party at any time during the Term upon the
declaration by a court of competent jurisdiction that the other Party is bankrupt and, pursuant to the U.S. Bankruptcy Code such other Party’s assets are to be liquidated; upon the filing or institution of bankruptcy, liquidation or
receivership proceedings (other than reorganization proceedings under Chapter 11 of the U.S. Bankruptcy Code); or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; or in the event a receiver
or custodian is appointed for such Party’s business; provided, however, that in the case of any involuntary proceeding, such right to terminate shall only become effective if the proceeding is not dismissed within sixty (60) days
after the filing thereof. 
 11.5 Termination of License Agreement. This Agreement shall automatically terminate upon expiration or
termination of the License Agreement. 
 11.6 Consequences of Expiration and Termination. 

11.6.1 Upon expiration or termination of this Agreement, except as set forth in this Section 11.6 or Section 11.7, all
obligations of the Parties under this Agreement will terminate immediately. The use by either Party of a termination right provided for under this Agreement and in accordance with this Agreement shall not give rise to the payment of damages or any
other form of compensation or relief to the other party with respect thereto. Subject to the preceding sentence, termination of this Agreement shall not preclude either Party from claiming any other damages, compensation or relief that it may be
entitled to upon such termination or for any breach of this Agreement. 
 11.6.2 Upon expiration or termination of this Agreement
(a) all unfilled Purchase Orders shall be cancelled; provided, that if Horizon terminates this Agreement pursuant to Section 11.2, at its option, Horizon may require that all unfilled Purchase Orders be delivered in accordance with
the terms of this Agreement and (b) Horizon shall promptly pay to AstraZeneca (i) the cost of AstraZeneca’s then existing inventory of Raw Materials that cannot otherwise be used in the business of AstraZeneca or returned to the
vendor without additional costs and the cost that AstraZeneca or any Pass-Through Affiliate is required to pay to a Pass-Through Supply Vendor with respect to such Pass-Through Supply Vendor’s then existing inventory of Raw Materials that
cannot otherwise be used in the business of such Pass-Through Supply Vendor or returned to the vendor without additional costs and (ii) the applicable Transfer Price for all work in process and finished Supplied Product Manufactured, but not
then delivered by AstraZeneca to Horizon; provided all such Raw Materials, work in process, and finished Supplied Product Manufactured but not then delivered by AstraZeneca to Horizon, shall be delivered to Horizon or its designee within
thirty (30) days. 
 11.7 Surviving Obligations. Expiration or termination of this Agreement will not relieve the Parties of any
obligation accruing prior to such expiration or termination. The provisions of Sections 2.3 (Technology Transfer) (only for six (6) months after the end of the Term), 9.4 (Disclaimer of Warranties), 10 (Confidentiality), 11.6 (Consequences of
Expiration 

  
 15. 

 
and Termination), 11.7 (Surviving Obligations), 12 (Indemnification and Insurance), 13 (Limitation of Liability) and 14 (Miscellaneous) will survive any expiration or termination of this
Agreement. 
 12. INDEMNIFICATION AND INSURANCE 

12.1 Indemnification by AstraZeneca. Subject to this Article 12, AstraZeneca shall indemnify, defend and hold harmless Horizon and its
Affiliates, and its and their respective licensors, licensees, officers, directors, employees and agents (collectively, “Horizon Indemnitees”) from and against any and all Losses incurred by them in connection with any and
all Litigation by Third Parties (collectively, “Third Party Claims”) arising from or occurring as a result of: (a) the gross negligence or willful misconduct of any AstraZeneca Indemnitee or (b) the breach by
AstraZeneca of any warranty, representation, covenant or agreement made by AstraZeneca in this Agreement, in each case, except to the extent such Losses result from the gross negligence or willful misconduct of any Horizon Indemnitee or the breach
by Horizon of any warranty, representation, covenant or agreement made by Horizon in this Agreement, as to which Losses each Party shall indemnify the other Party and the AstraZeneca Indemnitees or the Horizon Indemnitees, as applicable, to the
extent of its liability for such Losses. 
 12.2 Indemnification by Horizon. Subject to this Article 12, Horizon shall indemnify,
defend and hold harmless AstraZeneca and its Affiliates, and its and their respective officers, directors, employees and agents (collectively, “AstraZeneca Indemnitees”) from and against any and all Losses incurred by them in
connection with any and all Third Party Claims arising from or occurring as a result of: (a) the Exploitation or Manufacture of any Supplied Product by Horizon, its Affiliates or any of their respective Sublicensees, (b) the gross
negligence or willful misconduct of any Horizon Indemnitee, or (c) the breach by Horizon of any warranty, representation, covenant or agreement made by Horizon in this Agreement; except, in each case, to the extent such Losses result from the
gross negligence or willful misconduct of any AstraZeneca Indemnitee or the breach by AstraZeneca of any warranty, representation, covenant or agreement made by AstraZeneca in this Agreement, as to which Losses each Party shall indemnify the other
Party and the AstraZeneca Indemnitees or the Horizon Indemnitees, as applicable, to the extent of its liability for such Losses. 
 12.3
Indemnification Procedures. All indemnification claims in respect of Horizon or any Horizon Indemnitees shall be made solely by Horizon and all indemnification claims in respect of AstraZeneca or any AstraZeneca Indemnitee shall be made solely
by AstraZeneca and, in each case, shall be governed by Section 7.2 of the Asset Purchase Agreement. Notwithstanding anything herein to the contrary, the Parties’ respective indemnification obligations under this Article 12 shall not apply
to any Losses for which such Party is entitled to indemnification under the Asset Purchase Agreement (excluding for this purpose, application of the limitations in Section 7.3 of the Asset Purchase Agreement). 

12.4 Insurance. Each Party will have and maintain such types and amounts of liability insurance as is normal and customary in the
industry generally for parties similarly situated, and will upon request provide the other Party with a copy of its policies of insurance in that regard, along with any amendments and revisions thereto. 

  
 16. 

 13. LIMITATION OF LIABILITY 

13.1 [...***...] 
 13.2
NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, WITH RESPECT TO ANY LOSSES OR DAMAGES UNDER THIS AGREEMENT THAT [...***...] OF ANY [...***...] WITH RESPECT TO SUCH [...***...] TO THE [...***...] IN THE [...***...]; PROVIDED THAT
[...***...] WITH RESPECT TO [...***...] WITH THE [...***...]. 
 14. MISCELLANEOUS 

14.1 AstraZeneca’s Third Party Manufacturers. The Parties acknowledge and agree that AstraZeneca plans to use the Pass-Through
Supply Vendors in connection with the supply of Supplied Products under this Agreement and that AstraZeneca’s obligations, and Horizon’s rights, under this Agreement are subject to the terms and conditions of the applicable Pass-Through
Supply Agreements. AstraZeneca shall not amend any Pass-Through Supply Agreement in a manner that materially and adversely affects Horizon’s rights under this Agreement and the Quality Agreement nor terminate any such Pass-Through Supply
Agreement if such termination materially and adversely affects Horizon’s rights under this Agreement, in either case, without prior written consent of Horizon, such consent not to be unreasonably conditioned, withheld or delayed. 

14.2 Governing Law, Jurisdiction, Venue and Service. 

14.2.1 Governing Law. This Agreement shall be governed by and construed in 

  
  

	***	Confidential Treatment Requested 

 17. 

 
accordance with the Laws of the State of New York, excluding any conflicts or choice of Law rule or principle that might otherwise refer construction or interpretation of this Agreement to the
substantive Law of another jurisdiction. 
 14.2.2 Jurisdiction. Subject to Section 14.3 and 14.13, the Parties hereby
irrevocably and unconditionally consent to the exclusive jurisdiction of the courts of the State of New York and the United States District Court for the Southern District of New York for any action, suit or proceeding (other than appeals therefrom)
arising out of or relating to this Agreement, and agree not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts. The Parties irrevocably and unconditionally waive their right to a jury
trial. 
 14.2.3 Venue. Subject to Section 14.3 and 14.13, the Parties further hereby irrevocably and unconditionally
waive any objection to the laying of venue of any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the courts of the State of New York or in the United States District Court for the Southern
District of New York, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. 

14.2.4 Service. Each Party further agrees that service of any process, summons, notice or document by registered mail to its
address set forth in Section 14.4 shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any court. 

14.3 Dispute Resolution. 

14.3.1 Except as provided in Section 14.13, if a dispute arises between the Parties in connection with or relating to this
Agreement or any document or instrument delivered in connection herewith (a “Dispute”), then either Party shall have the right to refer such Dispute to the Senior Officers for attempted resolution by good faith negotiations
during a period of 10 Business Days. Any final decision mutually agreed to by the Senior Officers in writing shall be conclusive and binding on the Parties. 

14.3.2 If such Senior Officers are unable to resolve any such Dispute within such 10-Business Day period, either Party shall be free to
institute binding arbitration in accordance with this Section 14.3.2 upon written notice to the other Party (an “Arbitration Notice”) and seek such remedies as may be available. Upon receipt of an Arbitration Notice by a
Party, the applicable Dispute shall be resolved by final and binding arbitration before a panel of three (3) experts with relevant industry experience (the “Arbitrators”). Each of Horizon and AstraZeneca shall promptly
select one Arbitrator, which selections shall in no event be made later than thirty (30) days after the notice of initiation of arbitration. The third Arbitrator shall be chosen promptly by mutual agreement of the Arbitrator chosen by Horizon
and the Arbitrator chosen by AstraZeneca, but in no event later than thirty (30) days after the date that the last of such Arbitrators was appointed. The Arbitrators shall determine what discovery will be permitted, consistent with the goal of
reasonably controlling the cost and time that the Parties must expend for discovery; provided that the Arbitrators shall permit such discovery as they deem necessary 

  
 18. 

 
to permit an equitable resolution of the Dispute. The arbitration shall be administered by the American Arbitration Association (“AAA”) (or its successor entity) in
accordance with the then current Commercial Rules of the American Arbitration Association including the Procedures for Large, Complex Commercial Disputes (including the Optional Rules for Emergency Measures of Protection), except as modified in this
Agreement. The arbitration shall be held in New York, New York, USA, and the Parties shall use reasonable efforts to expedite the arbitration if requested by either Party. The Arbitrators shall, within fifteen (15) days after the conclusion of
the arbitration hearing, issue a written award and statement of decision describing the essential findings and conclusions on which the award is based, including the calculation of any damages awarded. The decision or award rendered by the
Arbitrators shall be final and non-appealable, and judgment may be entered upon it in accordance with applicable Law in the State of New York or any other court of competent jurisdiction. The Arbitrators shall be authorized to award compensatory
damages, but shall not be authorized to reform, modify or materially change this Agreement or any other agreements contemplated hereunder. 

14.3.3 Each Party shall bear its own counsel fees, costs, and disbursements arising out of the dispute resolution procedures described
in this Section 14.3, and shall pay an equal share of the fees and costs of the Arbitrators and all other general fees related to any arbitration described in Section 14.3.3; provided, however, the
Arbitrators shall be authorized to determine whether a Party is the prevailing Party, and if so, to award to that prevailing Party reimbursement for its reasonable counsel fees, costs and disbursements (including expert witness fees and expenses,
photocopy charges, or travel expenses) and/or the fees and costs of the Arbitrators. Unless the Parties otherwise agree in writing, during the period of time that any arbitration proceeding described in Section 14.3.3 is pending under this
Agreement, the Parties shall continue to comply with all terms and provisions of this Agreement. All arbitration proceedings and decisions of the Arbitrator under this 14.3 shall be deemed Confidential Information of both Parties under
Section 10. For clarity, nothing contained in this Agreement shall deny either Party the right to seek injunctive or other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective
irreparable harm, and such an action may be filed and maintained notwithstanding any ongoing arbitration proceeding.  
 14.4
Notice Requirements. Any notice, request, demand, waiver, consent, approval or other communication permitted or required under this Agreement (each, a “Notice”) shall be in writing, shall refer specifically to this
Agreement and shall be deemed given only if delivered by hand or sent by facsimile transmission (with transmission confirmed) or by internationally recognized overnight delivery service that maintains records of delivery, addressed to the Parties at
their respective addresses specified in this Section 14.4 or to such other address as the Party to whom notice is to be given may have provided to the other Party at least five (5) days’ prior to such address taking effect in
accordance with this Section 14.4. Such Notice shall be deemed to have been given as of the date delivered by hand or internationally recognized overnight delivery service or confirmed that it was received by facsimile (with receipt confirmed
by telephone or email). Any Notice delivered by facsimile shall be confirmed by a hard copy delivered as soon as practicable thereafter. 

  
 19. 

 If to AstraZeneca, to: 

AstraZeneca LP 

1800 Concord Pike 

Wilmington, Delaware 19803 

USA 

Attention: General Counsel 

Facsimile: (302) 886-1578 

With a copy (which shall not constitute notice) to: 

and to: 

Covington & Burling LLP 

1201 Pennsylvania Avenue, N.W. 

Washington, DC 20004 

Facsimile: (202) 662-6291 

Attention: John Hurvitz 

        Michael J. Riella 

If to Horizon, to: 

Horizon Pharma USA, Inc. 

520 Lake Cook Road, Suite 520 

Deerfield, Illinois 60015 

USA 

Attention: Chief Executive Officer 

Facsimile: 847-572-1372 

With a copy (which shall not constitute notice) to: 

Cooley LLP 

4401 Eastgate Mall 

San Diego, California 92121 

USA 

Attention: L. Kay Chandler, Esq. 

Facsimile: 858-550-6420 

14.5 Force Majeure. Neither Party shall be held liable or responsible to the other Party or be deemed to have defaulted under or
breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement if such failure or delay is caused by or results from events beyond the reasonable control of the non-performing Party, including fires, floods,
earthquakes, hurricanes, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorist acts, insurrections, riots, civil commotion, strikes, lockouts, or other labor disturbances (whether involving the
workforce of the non-performing Party or of any other Person), acts of God or acts, omissions or delays in acting by any 

  
 20. 

 
Governmental Authority (except to the extent such delay results from the breach by the non-performing Party or any of its Affiliates of any term or condition of this Agreement) (each, a
“Force Majeure Event”). The non-performing Party shall notify the other Party of such Force Majeure Event within thirty (30) days after such occurrence by giving written notice to the other Party stating the nature of
the Force Majeure Event, its anticipated duration, and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than is necessary and the non-performing Party shall use
commercially reasonable efforts to remedy its inability to perform. 
 14.6 No Benefit to Third Parties. The covenants and agreements
set forth in this Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and, except for the rights of Horizon Indemnitees and AstraZeneca Indemnitees under Article 12, they shall not be construed as conferring
any rights on any other Persons. 
 14.7 Waiver and Non-Exclusion of Remedies. Any term or condition of this Agreement may be waived
at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver by either Party of
any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other Party whether of a similar nature or otherwise.  

14.8 Assignment. Except as expressly set forth in this Agreement, neither Party shall have the right or the power to assign, in whole or
in part, any of its rights, or delegate the performance of any of its obligations, under this Agreement without the prior written authorization of the other Party, which authorization shall not be unreasonably withheld, conditioned or delayed, and
any assignment or delegation of this Agreement or any of such rights or obligations without such authorization shall be void and of no effect; provided, however, that either Party may assign the Agreement,
in whole or in part, to an Affiliate without the prior written authorization of the other Party; and provided, further, that either Party shall have the right to assign this Agreement, in whole or in part,
in connection with a merger or other acquisition of the capital stock or all or substantially all of its assets, without the prior written authorization of the other Party. Any permitted assignment or delegation hereunder by a Party shall not
relieve such Party of any of its obligations under this Agreement (whether by operation of law or otherwise), unless, with respect an assignment to a Third Party, such assignee agrees in writing to assume such Party’s obligations under this
Agreement, in which case such Party shall be relieved of its obligations hereunder from and after the effective date of such assignment and assumption. Subject to the foregoing, this Agreement shall be binding upon, inure to the benefit of, and be
enforceable by, the Parties and their respective successors and permitted assigns. 
 14.9 Use of Affiliates. Either Party
shall have the right to exercise its rights and perform its obligations under this Agreement either itself or through any of its Affiliates without authorization of the other Party. For clarity, AstraZeneca is permitted to perform its obligations
hereunder using any Pass-Through Supply Vendor. 

  
 21. 

 14.10 Amendment. This Agreement may not be modified, amended, altered or supplemented
except upon the execution and delivery of a written agreement executed by both Parties. 
 14.11 Independent Contractors. In
the exercise of their respective rights, and the performance of their respective obligations, under this Agreement, the Parties are, and shall remain, independent contractors. Nothing in this Agreement shall be construed to constitute the Parties as
partners, joint venturers, or participants in a joint enterprise or undertaking, or to constitute either of the Parties as the agent of the other Party for any purpose whatsoever. Neither Party shall bind, or attempt to bind, the other Party hereto
to any contract or the performance of any other obligation, or represent to any Third Party that it is authorized to enter into any contract or binding obligation on behalf of the other Party hereto. 

14.12 Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future Law,
and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a) such provision shall be fully severable, (b) this Agreement shall be construed and enforced as if such
illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or
by its severance herefrom and (d) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such illegal, invalid
or unenforceable provision as may be possible and reasonably acceptable to the Parties. 
 14.13 Equitable Relief. The Parties
agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to
an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in any court of the United States or any state having jurisdiction, this being in addition to any other remedy
to which they are entitled at law or in equity. Each Party hereby waives (a) any requirement that the other Party post a bond or other security as a condition for obtaining any such relief, and (b) any defenses in any action for specific
performance, including the defense that a remedy at law would be adequate. 
 14.14 English Language. This Agreement shall be
written and executed in, and all other communications under or in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof, and in the event of any conflict in
interpretation between the English version and such translation, the English version shall control. 
 14.15 Counterparts. This
Agreement may be executed in any number of counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement. Delivery of an executed counterpart of a
signature page of this Agreement by facsimile or other electronic transmission shall be effective as delivery of a manually executed original counterpart of this Agreement. 

14.16 Entire Agreement. This Agreement, together with the Schedules and Exhibits 

  
 22. 

 
expressly contemplated hereby and attached hereto, the Ancillary Agreements, the Confidentiality Agreement and the other agreements, certificates and documents delivered in connection herewith or
therewith or otherwise in connection with the transactions contemplated hereby and thereby, contain the entire agreement between the Parties with respect to the transactions contemplated hereby or thereby and supersede all prior agreements,
understandings, promises and representations, whether written or oral, between the Parties with respect to the subject matter hereof and thereof. In the event of any inconsistency between any such Schedules and Exhibits and this Agreement, the terms
of this Agreement shall govern. 
 14.17 Construction. Except where the context otherwise requires, wherever used, the singular
includes the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). The captions of this Agreement are for convenience of reference only and in
no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including” as used herein does not limit the generality of any description preceding such
term. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party. Unless otherwise specified or where the context otherwise requires,
(a) references in this Agreement to any Article, Section, Schedule or Exhibit are references to such Article, Section, Schedule or Exhibit of this Agreement; (b) references in any Section to any clause are references to such clause of such
Section; (c) “hereof,” “hereto,” “hereby,” “herein” and “hereunder” and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision
of this Agreement; (d) references to a Person are also to its permitted successors and assigns; (e) references to a Law include any amendment or modification to such Law and any rules or regulations issued thereunder, in each case, as in
effect at the relevant time of reference thereto; (f) references to any agreement, instrument or other document in this Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently amended, replaced
or supplemented from time to time, as so amended, replaced or supplemented and in effect at the relevant time of reference thereto; and (g) references to monetary amounts are denominated in United States Dollars. 

[Remainder of page intentionally left blank. Signature page follows.] 

  
 23. 

 IN WITNESS WHEREOF, the
Parties have executed this SUPPLY AGREEMENT by their respective authorized representatives as of the date first written above. 

 

							
	HORIZON PHARMA USA, INC. 	 	ASTRAZENECA LP
				
	By:	 	/s/ Timothy P. Walbert	 	By:	 	/s/ Steve Mohr
	Name:	 	Timothy P. Walbert	 	Name:	 	Steve Mohr
	Title:	 	President and Chief Executive Officer	 	Title:	 	 Deputy General Counsel, North America and US General Counsel

 SIGNATURE PAGE TO SUPPLY AGREEMENT

 SCHEDULE 1.41 

PACKAGING TECHNOLOGY 

[...***...] 

  
  

	***	Confidential Treatment Requested 

  

 SCHEDULE 1.44 

PASS-THROUGH SUPPLY AGREEMENTS 

[...***...] 

  
  

	***	Confidential Treatment Requested 

  

 SCHEDULE 1.49 

PRODUCT SPECIFICATIONS 

(SEE ATTACHED) 

 SCHEDULE 3.1.1 

INITIAL FORECAST 
  

																									
	 Vimovo
	  	2014
	  	 JAN
	  	FEB	  	MAR	  	APR	  	MAY	  	JUN	  	JUL	  	AUG	  	SEP	  	OCT	  	NOV	  	DEC
	 Order Forecast
	  		  		  		  		  		  		  		  		  		  	
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

 [...***...] 

  
  

	***	Confidential Treatment Requested 

  

 SCHEDULE 3.2.2 

INITIAL PURCHASE ORDER 

 

									
	 Vimovo
	  	2014
	  	JAN	  	FEB	  	MAR	  	APR
	 Purchase Order

	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

 [...***...] 

  
  

	***	Confidential Treatment Requested 

  

 SCHEDULE 4.1 

TRANSFER PRICES 

Supplied Product: 
  

					
	 SKU
	  	Cost per Tablet	  	Cost per SKU
	[...***...]	  	[...***...]	  	[...***...]
	[...***...]	  	[...***...]	  	[...***...]
	[...***...]	  	[...***...]	  	[...***...]

  
  

	***	Confidential Treatment Requested 

 . 

 SCHEDULE 9.2(A) 

THIRD PARTY MANUFACTURERS 

[...***...] 

  
  

	***	Confidential Treatment Requested 

  

 EXHIBIT A 

PATHEON SIDE LETTER 

(SEE ATTACHED)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]